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ABSTRACT 
The number of patients undergoing allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) is steadily increasing, and the outcome of this intervention is largely 
dependent on how well complications in the form of severe infections can be 
adequately diagnosed and controlled. Adenoviruses (AdV) have emerged as important 
causes of morbidity and mortality in these patients. Early diagnosis of the infection by 
detection of viral DNA may improve the prognosis. In paper I we evaluated a 
surveillance strategy for detection of AdV DNA by real-time PCR in a prospective 
study of hematological allo-HSCT recipients. In parallel with a routine 
cytomegalovirus surveillance program, plasma samples from 97 recipients were 
analyzed by quantitative PCR for detection of AdV DNA. A total of 5% of the patients 
had detectable AdV DNA in plasma. Only one patient had high titers and none 
developed AdV disease. Bone marrow as a source of stem cells and myelodysplastic 
syndrome as the indication for transplantation were independently associated with 
higher risk of acquiring AdV infection. We concluded that the strategy did not have a 
significant effect on the clinical outcome in our material, but given the sometimes high 
incidence of AdV infection and disease in other settings, we do not dismiss the idea of 
surveillance. With a somewhat different approach to improve the clinical care for 
patients undergoing immunosuppressive treatment, we investigated the etiology to 
febrile neutropenia. Chemotherapy-induced neutropenia is one of the major side effects 
of the treatment of maligancies, and the risk of infection is increased by the severity 
and duration of neutropenia. The empiric administration of broad spectrum antibiotics 
has substantially decreased the mortality rate of patients with febrile neutropenia, but in 
only approximately one-third or fewer of the fever episodes, bacterial infection is 
documented. It is likely that other pathogens, such as viruses, play an important role as 
etiological agents, and an overuse of antibiotics could be anticipated. Therefore, in 
paper II and paper IV we investigated the presence of common viral infections and 
febrile neutropenia in children with cancer as well as adult patients with hematological 
disorders. A broad range of respiratory viruses in nasopharyngeal aspirate (NPA) and 
viruses commonly reactivated in allo-HSCT recipients were sought for. With human 
rhinovirus (HRV) being the predominant virus, we found an viral agent in half of the 
cases in the pediatric cohort. Of these, 25% co-ocurred with a bacterial finding. Virus 
detcted in blood was a rare event. In the adult population, we detected a viral pathogen 
in 42% of the episodes of febrile neutropenia. This should be compared to 13% in 
afebrile neutropenic patients that were included as controls. In both groups, 
approximately half of the viruses were detected in blood. The predominant respiratory 
virus was HRV, whereas BK virus was the commonest finding in blood. In one-third of 
the virus-positive cases, a bacterial infection was documented. We furthermore found 
NPA being superior to a flocked nasal swab for collection of respiratory specimens 
(paper III).  We concluded that the prevalence of viruses was high in neutropenic 
patients with fever, and it was higher than for neutropenic patients without fever. It is 
plausible that a number of the patients with febrile neutropenia suffer from viral 
infections, and are thus not helped by antibiotics. Unfortunately, the presence of virus 
could not function as a predictor for non-bacterial infection. The findings, however, 
warrants further research related to the earlier achievements with aim to identify 
patients where continuous empiric antibiotic treatment could be avoided. 
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1 INTRODUCTION 
 
A beginning exists - at least for biological life on planet earth. About four billion years 
ago, lifeless molecules formed cells, the structural and functional units of all living 
organisms with the ability to reproduce themselves. At some later stage, relatively 
simple unicellular organisms became multicellular, and the cells began to differentiate 
to form organs working together in more complex organisms. All shapes of life were 
targets for invaders and, to be a lucky member of the fittest, defense mechanisms were 
developed in order to kill or live side by side with the trespassers [1]. Thus, the immune 
system that keeps you alive today is the result of a billion-year project – a diamond that 
was polished on the beaches of Rodinia and Pangæa. 
 
Recently in this perspective, during World War II, the chemical warfare agent, nitrogen 
mustard, leaked out from a U.S. liberty ship after a German air raid in Italy. Autopsies 
of the victims revealed results suggesting a profound suppression of cell types that 
normally divided rapidly. With this knowledge, two pharmacologists set up an animal 
model where they treated cancer with mustard agents [2], and ever since, antineoplastic 
drugs have dominated the treatment of cancer in humans. A myth or not, the story 
reflects the time point of the discovery of antineoplastic chemotherapy [3]. Although 
the drugs have been refined, the adverse effects are severe; the carefully designed and 
frequently dividing immune cells are also affected and, subsequently, infections are the 
major cause of morbidity and mortality beside the cancer itself. 
 
Even when taking the time span of the immune system’s development into 
consideration, the excellence of the system is so inconceivable that neither Darwin’s 
theory nor other, less scientific, explanations make the success comprehensible. 
Fortunately, that mystery is beyond the scope of this thesis which will mainly focus on 
certain infections in cancer patients being immunodeficient due to anti-cancer 
treatment. However, keeping a larger picture in mind will help us understand the 
magnitude of the problem that infections cause in immunocompromised individuals. 
 2 
2 BACKGROUND 
 
2.1 IMMUNOLOGY 
 
As described in the introduction section, the immune system is the result of many years 
of evolution. One part, the non-specific, is rather static and retains the same properties 
during an individual’s life. However, the other part, the specific immune system, has 
the ability to adapt to the current environment and so to say undergo an intra-individual 
evolution. In the following sections these two parts of the system are described in 
general and broad terms. 
 
 
2.1.1 The non-specific immune system 
 
The very first defense against infections would be the behavior; you do not go towards 
a sneezing or coughing person and you do not eat food that obviously been mishandled. 
However, avoiding any contact with pathogens is impossible. The body has to be in 
contact with its surrounding in order to exchange oxygen and carbon dioxide, reach 
nutrition and get rid of non-digestible food, eliminate ammonia, and to explore the 
environment. Thus, the respiratory and the gastro-intestinal epithelium, the urothelium, 
and the skin, respectively, are technically the outside of the body. Although these 
barriers are the first line of defense against pathogens and possess numerous of defense 
mechanisms [4-8], their cells are not usually addressed as “immunological”, a title they 
undoubtedly deserve! The non-specific immune system is non-specific in the sense that 
it contains mechanisms that exist before infection. However, as it is developed to 
protect from, in principle, all non-self structures it is specific regarding the selection of 
self and non-self. 
 
The cells that contribute to the rapid non-specific immune response are macrophages, 
neutrophils, and the natural killer (NK) cells. Macrophages and neutrophils use 
phagocytosis to eliminate their enemies, whereas the NK cells kill cells that cannot 
show that they are “self”. Some macrophages are distributed in the tissues to screen the 
surrounding whereas others are recruited to the tissue upon infection. The classical 
signs of inflammation are caused by the innate response, and the pus that may appear 
mainly consists of sacrificed neutrophils. Upon viral infections, one important part of 
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the innate response is the production of type I interferons (Figure 1a). These molecules 
set the cells in an “antiviral state” that minimizes the viral spread until an adequate and 
specific (adaptive) immune response is reached (Figure 1b). It further stimulates NK 
cell activity and facilitates the survival of dendritic cells that, via their antigen 
presentation, are one of the bridges between the non-specific and specific immune 
system [9]. 
 
 
 
 
 
 
Figure 1a. A simplified schematic illustration of a host cell’s recognition of, and 
immunological response to, viruses (blue stars). Membrane-bound Toll-like receptors 
(TLRs) on the cell surface can recognize certain viral protein structures, whereas TLRs 
in endosomal compartments are capable to detect different viral genomes. Other 
pattern recognition receptors are the RIG-I-like receptors (RLRs) that detect the viral 
genome in the cytoplasm. These two families of pattern recognition receptors comprise 
the front line of defense that the host possesses against viral pathogens. Among many 
other actions, the induced type I interferons increase the ability of uninfected host cells 
to resist the virus. 
 4 
 
 
 
Figure 1b. Simplified schematic illustration of the action of type I interferons. Viruses 
recognized by a host cell, induce production of type I interferons which have their 
action on nearby cells. Uninfected cells (to the right) are induced to produce type I 
interferons and anti-viral peptides, whereas already infected cells (to the left) undergo 
programmed cell death, apoptosis. Type I interferons also induce other cells to produce 
interferons. Finally, the response activates cells from the non-specific immune system. 
 
 
2.1.2 The complement system 
 
A number of proteins circulate as precursors in the bloodstream, ready to be cleaved 
and thus activated. In their active form they are able to facilitate the ability of 
antibodies and phagocytic cells to eliminate pathogens. Specific actions are either direct 
or indirect. Lysis of membranes of pathogens, clumping of the pathogens, and changing 
of viruses’ molecular structure are examples of direct actions independent of other 
mechanisms, whereas opsonization of pathogens and attraction of innate immune cells 
via chemotaxis enhance mechanisms from other parts of the immune system. Although 
it can be recruited and brought into action by the specific immune system, the 
complement system belongs to the non-specific part. The involved proteins do not 
adapt and the mechanism could therefore be addressed as a “non-specific humoral 
defense system”. The proteins are produced by the liver and use three different 
pathways for activation; the classical, alternate, and the mannose-binding lectin (MBL) 
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pathways [9]. A mutation leading to an altered MBL production is suggested to be a 
risk factor for severe infections and fever in immunocompromised patients [10]. This is 
however controversial and a recent summary of the literature conclude that MBL could 
not be identified as an independent risk factor [11]. 
 
 
2.1.3 The specific immune system 
 
The components of the specific immune system are lymphocytes and their products. 
The number of lymphocytes in the human body is huge – 1000 billions with a 
cumulative weight of 500 grams and the size of the liver! This part of the immune 
system first appeared in jawed vertebrates and is thus much younger than the innate 
part. The specific immune response could be divided into the humoral and cell-
mediated immunity achieved by the B cells and the T cells, respectively. 
 
The humoral response is mediated by antibodies produced by certain B cells. The 
antibodies recognize specific antigens on the invaders, and can have two actions; 
neutralization of the infectivity of the microbes, and opsonization of the microbes for 
elimination by other mechanisms. For obvious reasons, the humoral defense is the 
principle mechanism against extracellular microbes and their toxins. However, it plays 
an important role in the defense against intracellular infections as well. 
 
The cellular immunity mediated by the T cells has its impact on intracellular pathogens 
such as viruses and some bacteria. Instead of using neutralizing antibodies, cytotoxic T 
cells promote destruction of microbes residing in phagocytes, but also induce lysis of 
infected cells. When a dendritic cell from the innate system shows an antigen in its 
receptor, it has to interact with the correct lymphocyte in order to initiate a 
proliferation. This “meeting” is made possible by the concentration of lymphocytes to 
the lymphoid tissues, but is still somewhat equivalent to finding a needle in a haystack. 
 
A simple explanation does not exist why the B cells and the T cells can be uniquely 
designed for specific pathogens or infected cells. In summary, due to gene 
recombination, the receptors on these cells are unique for each single cell. Via selection 
processes, only the lymphocytes with two important features survive; the ability to 
“shake hands” with the host cells in a descent way, and to distinguish “self” from “non-
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self”. Thus, the high number of lymphocytes and their uniqueness explain why there is 
at least one specific lymphocyte for each pathogen circulating. Those who cannot 
remember the past are condemned to repeat it, and one most important feature of the 
adaptive immune system is its ability to “remember” past infections. Keeping a pool of 
memory cells enables a much faster specific response upon re-infection. The specific 
immune response is essential for elimination of viral infections [9]. 
 
 
2.1.4 Fever 
 
The oldest known written reference to fever exists in inscriptions from the sixth century 
BC, with a flaming brazier that symbolized fever and the local warmth of 
inflammation. Roman military physicians also wrote of the resolution of fever in 
soldiers once pus was drained [12]. Fever is defined as an elevation of the body 
temperature above the normal range caused by a changed thermoregulatory set-point in 
hypothalamus. Just like a triggered thermostat, the brain sends signals to different 
mechanisms, such as shivering or vasoconstriction, in order to increase the body 
temperature. Molecules able to change the set-point, and thus induce fever, are called 
pyrogens and can be either endogenous (cytokines from the innate immune system) or 
exogenous (e.g. bacterial endotoxins). Most important endogenous pyrogens are 
interleukin (IL)-1, IL-6, and TNF-α, but other minor pyrogens, such as IL-8 and type II 
interferons, can also cause fever [13]. Also type I interferons, important cytokines in 
viral infections, are known to induce fever [14]. However, although it is not debated 
that infections in many situations cause fever, the classical mechanisms described 
above are debated [15]. 
 
Questions about the fever’s benefit have generated considerable controversy during the 
years because of substantial data indicating potentiating and inhibitory effects of the 
response on resistance to infection. As a result, there is no consensus about the 
appropriate clinical situations in which fever or its mediators should be suppressed [16, 
17]. 
 
Most people associate fever with infectious diseases, but also other conditions 
sometimes go with fever; neoplasms (e.g. lymphomas), inflammatory diseases (e.g. 
temporal arthritis), drug fevers (e.g. cytarabine). Differentiation between these types of 
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fever is one of the challenges within the clinical care of patients with febrile 
neutropenia. 
 
 
2.2 CANCER IN CHILDREN 
 
Cancer is a rare event in children compared to adults, but this fact is of course of little 
consolation to those approximately 300 children and their families who are affected in 
Sweden every year [18, 19]. During the last 40 years we have seen a dramatic 
improvement of the results from treatments of cancer in children and adolescents. With 
a great variation between the different diseases, in Scandinavia, four out of five of these 
patients survive at least five years after diagnosis [20]. In contrast to cancers in adults, 
the pediatric cancers often develop in embryonic precursor cells [21]. Approximately 
half of the malignancies are leukemia, and brain and spinal tumor. The remaining types 
are lymphomas, sarcomas, neuroblastomas, Wilms tumors, retinoblastomas, germ cell 
tumors, and epithelial tumors [22]. The success of cancer treatment in children can be 
attributed mostly to powerful combinations of chemo (and radio) therapies as well as 
advances within cancer surgery. Unfortunately, tougher treatments are associated with 
more severe side-effects and complications which have required improvements in 
intensive care of the child and increased knowledge about infections [22]. A form of 
solid tumor that was frequent in the children in study II are described here, while 
hematological malignancies are found in the next chapter. 
 
 
2.2.1 Neuroblastoma 
 
Neuroblastoma is a tumor that affects young children. The median age at diagnosis is 
about two years, but it also appears that children are born with the disease. The tumor 
develops in the sympathetic part of the autonomic nervous system, and neuroblastoma 
can thus occur in almost any part of the body; most commonly in the adrenal gland. 
Symptoms are often absent and the disease is instead detected by noticing a resistance. 
Sometimes the tumor secretes hormones that can cause diarrhea, sweating and other 
symptoms. Moreover, the tumor can press on other organs and thus cause symptoms. 
Simplified, the treatment is based on the classification of the disease; benign, moderate 
or aggressive. Surgery and observation is used in benign cases, whereas in more 
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advanced diseases treatment with chemotherapy, surgery, radiotherapy, autologous 
hematopoietic stem cell transplantation (HSCT), or 13-cis retinoic acid is employed. 
 
 
2.3 HEMATOLOGICAL DISORDERS IN CHILDREN AND ADULTS 
 
Generating 300 billions of blood cells daily, the production of red and white blood cells 
is of enormous proportion. Being a minority in the bone marrow, the hematopoietic 
stem cells have the capacity to replace the blood hundreds of times during a normal life 
span. Hematology is the subspecialty of internal medicine that deals with etiology, 
diagnosis, treatment, prognosis, and prevention of disorders of the blood and the blood-
forming organs. 
 
 
2.3.1 Disorders 
 
Hematological disorders are divided into groups and subgroups by different 
classifications. In the sections below the most common disorders from our patient 
cohorts are described. 
 
 
2.3.1.1 Lymphoma 
 
Back in 1832 the pathologist Thomas Hodgkin described the Hodgkin lymphoma (HL). 
This lymphoma should be followed by several additional forms. Thirty years ago, a 
consensus was reached to denote these additional lymphomas as non-Hodgkin 
lymphoma (NHL) [23, 24].  
 
 
2.3.1.1.1 Non-Hodgkin lymphoma 
 
A number of various different classification systems exist for lymphoma. NHL is a 
heterogeneous group of malignancies which is distinguished from the far less common 
HL. All NHL originate from lymphocytes or their precursors. One classification of 
NHL is based on the degree to which the “NHL cells” mimic the normal lymphocytes 
in different compartments of the lymph node, in bone marrow, in thymus, spleen, or 
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other lymphoid organs. Both small lymphocytic lymphoma (SLL) and chronic 
lymphocytic leukemia (CLL) arise from prefollicular B cells, but manifest in different 
ways; if the disease, in addition to lymph nodes or other solid organs, involves blood, it 
is called CLL. CLL is the most common lymphoid malignancy in our part of the world, 
characterized by an increase in fairly normal lymphocytes. As a disease of the elderly 
the majority of patients are more than 50 years old and the median age at presentation is 
about 65 years. Both SLL and CLL have a slow progress and are considered incurable. 
The patients can, however, often live a fairly normal life, and therapy is generally 
aimed towards relief of symptoms. This is also true for follicular lymphoma, another 
NHL that is common in the Western Hemisphere. The cells of large cell lymphomas 
mimic the largest cells in a normal follicle, but do not form lymphoid follicles and are 
thus called diffuse large B cell lymphoma. This is an aggressive malignancy that 
responds well to chemotherapy; roughly half of the patients are cured. Another highly 
aggressive lymphoma is the Burkitt lymphoma which is mentioned here since it is 
hypothesized that it originates in the germinal center. It responds to chemotherapy but 
relapse is unfortunately rather common. Mantle cell lymphoma shares some features 
with SLL and CLL and is also incurable. However, it is more aggressive and has a 
median survival of 3-5 years. Marginal zone lymphomas normally have an indolent 
progress, but even with intensive treatment regimens the median survival of 3 years 
have been difficult to improve. Some lymphomas display T cell phenotypes, but T cell 
lymphomas are a minority of the NHL. The NHL above can be divided into high- and 
low-malignant NHL; diffuse large B cell lymphoma is the most common high-
malignant, whereas SLL, CLL, and follicular lymphoma are common low-malignant 
NHL. 
 
NHL mostly affects middle-aged and elderly, but also children have the disease, 
foremost originated in precursor B cells. Typically, NHL presents with painless 
swelling of one or several lymph nodes or other lymphoid tissues. Additional 
symptoms (B-symptoms) include night sweats, fever and weight loss. For indolent 
NHL, the clinical approach is expectation with regular check-ups until symptoms 
appear. Chemotherapy, sometimes together with radiography, is used for treatment of 
more aggressive and generalized disease [23, 24] 
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2.3.1.1.2 Hodgkin lymphoma 
 
HL is a malignancy that arises in lymphoid tissues and account for less than 10% of all 
lymphomas. It is divided into two major groups; nodular lymphocyte predominance 
HL, and the far more common classical HL. Similar to NHL the majority of patients 
have painless swollen lymph nodes. Furthermore, depending on subtype, HL patients 
can show B-symptoms. The incidence is biphasic with peaks around 20 and 70 years of 
age. Depending on the stadium of the disease, the treatment consists of either or both of 
radio- and chemotherapy. Relapse can motivate autologous HSCT [23, 24]. 
 
 
2.3.1.2 Acute leukemia 
 
Acute leukemia is characterized by a neoplastic proliferation of immature 
hematopoietic cells in the bone marrow. These blasts accumulate and consequently 
suppress the normal hematopoiesis which leads to anemia, neutropenia, and 
thrombocytopenia. Fatigue, infections, and bleeding disorders, respectively, are 
therefore common manifestations. The blasts enter the bloodstream in varying extent 
and organs can be infiltrated. Furthermore, extremely high levels can cause 
microcirculation disturbance. Acute leukemia can be classified into two categories 
where acute lymphocytic leukemia (ALL) is by far more common in children than in 
adults. The opposite relationship is true for acute myeloid leukemia (AML). Other 
clinically important distinctions between these groups are the treatment and the 
prognosis [25]. 
 
  
2.3.1.2.1 Acute myeloid leukemia 
 
AML is a neoplasm of immature myeloid precursor cells, myeloblasts, and is further 
divided into seven subtypes based on differentiation. The incidence increases with age 
so that the median age of AML patients is about 65 years [26]. The prognosis is 
dependent on several factors such as age, cytogenic abnormalities in the leukemic 
blasts, history of bone marrow disorder, treatment-related AML, multidrug resistance, 
hyperleukocytosis at presentation, etc. Children and individuals over 60 years of age 
have a poorer prognosis. The treatments can be divided into two phases. The induction 
chemotherapy aim to eradicate the malignant cell and obtain so called complete 
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remission (CR). As blasts still exist after induction therapy, the postremission therapy is 
necessary to prevent relapse. This therapy can be of similar intensity as for the 
induction therapy or be more aggressive including high-dose chemotherapy, autologous 
HSCT, or allogeneic HSCT (allo-HSCT). The treatment of AML subtype M3, 
however, requires a totally different set of regimens [25].  
 
 
2.3.1.2.2 Acute lymphocytic leukemia 
 
As for AML, ALL can be divided into subtypes, L1-L3. ALL account for about 75% of 
all pediatric leukemias [27]. In contrast to AML in children, ALL has an excellent 
prognosis in the age between 2-9 years. Approximately one third of adults survive, but 
for patients older than 60 years of age the prognosis is worse. Infants also have a poor 
prognosis. Other factors also influence; cytogenetic abnormalities, immunophenotype, 
hyperleukocytosis at presentation, etc. Many drugs are active in ALL and most children 
are cured with standard chemotherapy - a success that is only partially achieved in 
adults. The regimen typically consists of a 2- to 3-year program including of a 
combination of several drugs, both intravenously and intrathecally. After first CR, high 
risk patients can be subjects for allo-HSCT [25]. 
 
 
2.3.1.3 Myelodysplastic syndrome 
 
Myelodysplastic syndrome (MDS) refers to a heterogeneous group of acquired bone 
marrow failure disorders that have a tendency to progress to AML. It is characterized 
by peripheral blood cytopenias with morphologic evidence of dysplasia in the bone 
marrow progenitor cells. Due to hypercellularity in the bone marrow, the hematopoiesis 
is ineffective. The incidence increases with age, and MDS is thus a disease of the 
elderly. No other interventions than allo-HSCT have been shown to extend survival of 
MDS patients. Unfortunately, being a disease of the elderly, many of the MDS patients 
are not suitable for allo-HSCT and supportive care alone often remains as the only 
option [25]. 
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2.3.2 Treatments 
 
There is a great variety of treatment protocols for hematological disorders, and often a 
combination of two or more drugs are used. The names of the regimens are 
abbreviations based on the containing substances. Examples are R-CHOP, DA, BEA-
COPP, ABCDV, MIME, etc. Described below are two regimens, DA and R-CHOP, 
which are commonly used for AML and NHL, respectively. The regimens include three 
groups of pharmacological agents with principally different immunosuppressive 
effects; antineoplastic drugs, monoclonal antibodies, and steroids. The abbreviated 
name DA stands for the substances Daunorubicin and Arabinofuranosyl Cytidine (Ara-
C), while R-CHOP consist of five drugs; Rituximab,  Cyclophosphamide, 
Hydroxydoxorubicin, Oncovin (brand name), and Prednisone. DA can be 
administrated as follows: induction treatment including Ara-C given intravenously in 
bolus doses or by continuous infusion over a period of seven days, and daunorubicin 
given intravenously in bolus doses for 3 days. Upon CR, the consolidation could 
consist of one or more cycles of high-dose Ara-C. Other post-remission therapeutic 
options are allo-HSCT, autologous HSCT or low-dose maintenance therapy. R-CHOP 
is often administered in cycles of 4 weeks. A common treatment regimen is for at least 
6 cycles. 
 
 
2.3.2.1 Antineoplastic chemotherapy 
 
Because cancer cells spend more time dividing than other cells, inhibiting cell division 
harms tumor cells more than other cells. The drugs described here have their primarily 
mode of action in altering cell division – acting antineoplastically. 
 
Daunorubicin, an anthracycline, is a potent cytostatic agent which primarily mode of 
action is intercalation of DNA. This inhibits the transcription, replication, and DNA 
repair processes in the cancer cells as well as other rapidly dividing cells. In addition to 
its major use in treating AML, daunorubicin is also used to treat other malignancies 
such as neuroblastoma. Being a synthetic analogous of the nucleoside deoxicytidin, 
Ara-C, inhibits the DNA-synthesis. Like daunorubicin the cytotoxic effect is linked to 
the substance’s ability to bind to DNA and inhibiting enzymes necessary for replication 
and transcription. One of the unique toxicities of cytarabine is cerebellar toxicity when 
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given in high doses. The mechanism of the alkaloid Oncovin (vincristine) is yet to be 
fully understood. A probable principle of vincristine’s cytostatic effect is the 
substance’s tubulin dimer binding capacity and the consequent metaphase mitosis 
arrest. Consequently, all the above mentioned agents are suppressing hematopoiesis 
which renders cytopenia and susceptibility to infection in the treated patients. 
 
 
2.3.2.2 Monoclonal antibodies 
 
Rituximab is a monoclonal antibody that can bind to CD20-antigen on pre-B and 
mature B-lymphocytes. CD 20 is present on all B-lymphocytes, malignant as well as 
normal cells, but not on hematopoietic stem cells. Thereby, the immune system is 
targeted for lysis of B-lymphocytes and the action is not myelosuppressive. The 
hematological side effects are thus primarily related to the reduced humoral responses. 
However, rituximab are seldom used as mono therapy in these patients. 
 
 
2.3.2.3 Corticosteroids 
 
Prednisone is a synthetic corticosteroid with effects on both the innate and adaptive 
immune response. The inflammation caused by the innate system is reduced due to a 
number of mechanisms, such as inhibition of the phospholipase cascade, and induction 
of a protein that inhibits the nuclear factor κB (NF-κB) (Figure 1a). By inhibiting the 
production of certain interleukins, prednisone alters the adaptive immune response in 
different ways. Pathways to an adequate humoral and cell-mediated response are 
affected. In contrast to the monoclonal antibodies this drug has a more general effect, 
but it is not antineoplastic.  
 
 
2.3.2.4 Allogeneic hematopoietic stem Cell Transplantation 
 
Allo-HSCT is a therapeutic procedure which has evolved enormously since its 
introduction over 50 years ago [28]. It was initially used as treatment for different 
immune deficiencies to add missing cell types, but is today also used as a cure for 
hematological malignant and non-malignant disorders. Examples of malignant 
 14 
indications are chronic myeloid leukemia (CML), MDS, AML, and CLL [29], whereas 
non-malignant disorders could be bone marrow failure and congenital red cell disorders 
[30]. 
 
In the beginning, only bone marrow was used as stem cell source and is still today the 
major source used in children [31]. However, after stimulation of the donor with 
granulocyte colony stimulating factor (G-CSF) which mobilizes stem cells from the 
bone marrow into the peripheral circulation, they can be harvested from peripheral 
blood. This method is predominantly used in adults [32-34]. Umbilical cord blood 
(UCB) is also used where the recipient often is a child or an adult missing a suitable 
donor [35-37]. Each of these three sources of stem cells have their own advantages and 
disadvantages. Bone marrow and peripheral blood can be donated again if necessary, 
but collecting bone marrow is performed under general anesthesia and can be a painful 
procedure. Using peripheral blood is associated with a rapid hematological recovery 
and low relapse rate, but has increased risk for chronic graft versus host disease. UCB 
is better suited for HLA (human leukocyte antigen) mismatch, but only a small number 
of cells are collected in each unit, and it is associated with a higher rate of non-
engraftment.   
 
The donors of the graft are preferably HLA-identical siblings, but in the absence of 
such, HLA-matched unrelated donors are an option. Therefore, several registries are 
developed containing volunteer donors. A haplo-identical parent is also a possible 
donor [38]. A high grade of mismatch between donor and recipient increases the risk of 
graft versus host disease (GVHD), but also a greater effect of graft versus malignancy 
(leukemia). Therefore, the seemingly best matched donor, an identical twin, is more 
suitable in non-malignant disorders [39, 40]. 
  
The initial treatment prior allo-HSCT aims to eradicate the disease, suppress immune 
reactions towards the graft, and eliminate the recipient hematopoietic stem cells to 
make place for the graft in the bone marrow. This procedure is referred to as the 
conditional (or preparative) regimen. Myeloablative conditioning (MAC) and reduced 
intensity conditioning (RIC) are the two major types of regimens. MAC consists of 
high dose of chemotherapy, alone or together with radiotherapy [41-43], which aim to 
directly but also indirectly, via graft-vs-malignancy effect, cure the disease. The 
treatment itself is more toxic compared to RIC but is associated with a lower risk for 
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relapse of certain malignancies [44, 45]. RIC is less toxic and are therefore used in 
patients that may not tolerate MAC (e.g. high age, organ dysfunction) but also where 
MAC would not be superior RIC to cure the disease [46-50]. Conditioning with RIC 
relies on the graft-vs-malignancy effect in a higher extent than does MAC. 
 
After transplantation engraftment, both the specific and non-specific immune system 
reconstitutes. This is however a tedious process that can take years [51-57], a period 
that the patient is extremely susceptible for almost all kinds of opportunistic infections. 
The skin and the mucous barriers as well as the innate immune system recover rapidly, 
and are not dependent on the compatibility of the donor and the recipient [58]. The 
engraftment, normally defined as a neutrophil count > 500 cells/mm3 for three days, 
takes place approximately one to two weeks after allo-HSCT and total recovery of the 
granulocyte, platelet, and NK cell numbers is achieved within a month [59]. The 
recovery of the specific immune system takes around one year [60] but some parts take 
even longer [61]. The reconstitution of the T cells is dependent on two mechanisms; (1) 
the expansion of already mature T cells infused via the graft which is important for 
protection against infections as well as graft rejection [62], and (2) de novo generation 
of thymic-dependent T cells which is the most important mechanism when a T cell 
depleted graft have been used [63]. 
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2.4 VIRAL DETECTION METHODS 
 
Four principally different methods are used to detect viral infections: 
 
1. Virus isolation 
2. Antigen detection 
3. Genome detection 
4. Serology 
 
The first relies on the viruses capability to replicate, thus viable viruses are required. 
The second and third can detect non-viable viruses and relies on detection of parts of 
the virus. The forth detects the immune response by the infected host as an indirect 
measure of an acute or past infection. With some exceptions, virus isolation, antigen 
detection methods, and serology are less frequently used today. Although they have 
several advantages, their limitations have made polymerase chain reaction (PCR), and 
foremost real-time PCR, the method of choice for viral detection in many settings 
(Table 1). The former methods are briefly presented below, whereas real-time PCR is 
described more in detail. 
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Table 1. Advantages and disadvantages of four different viral detection methods 
 Advantages Disadvantages 
Virus isolation 
 - High sensitivity for several viruses 
- Can detect other viruses than the 
expected when use of several cell 
lines 
- Not very sensitive for changes in 
the viral genome 
- A positive result, indicate viable 
viruses 
 
- Requires trained personnel 
- Requires special equipment in special 
laboratories 
- Time to detection is for most respiratory 
viruses about a week 
- Requires viable viruses 
- Some viruses are difficult or impossible 
to isolate 
Antigen detection (here represented by IF)  
 - Rapid 
- Relatively inexpensive 
- Has high sensitivity and specificity 
- A sufficient amount of epithelial cells 
are required 
- Needs trained personnel 
- Validated antibodies for certain viruses 
are missing 
 
Serology 
 - Sensitive 
- Indicate actual infection 
- Capable to detect previous 
infections 
 
- Time to result is >10 days when it 
requires a paired follow-up sample  
Real-time PCR 
 - Sensitive and specific 
- Relatively fast 
- Any virus can be detected 
depending on the design 
- Relatively inexpensive 
- Even dead viruses could reveal 
positive results 
- Even dead viruses could reveal positive 
results 
- So sensitive that positivity can be of no 
clinical relevance 
- Unable, in principle, to detect viruses 
not designed to 
-Could be false negative due to mutations 
NOTE. IF, immunofluorescence; PCR, polymerase chain reaction. 
 
  
 
 
2.4.1 Virus isolation, antigen detection, and serology 
 
Virus isolation has been the golden standard for many years. Different cell lines 
susceptible to several viruses are used for inoculation of infected host specimen. 
Positivity is determined by a certain pattern of swelling or destruction of the cultured 
cells (cytopathic effect). The pattern is specific for each virus and it is thus only a 
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trained virologist who can recognize a positive sample. The work is labor-intense and it 
takes days to weeks before a result can be provided; a sometimes unacceptable turn-
around time for the treating physician [64]. 
 
Enzyme-linked immunosorbent assay (ELISA) is an antigen detection method that is 
carried out by first inoculating the patient sample on a surface. Roughly, the further 
procedure continues by either pre-coating the surface with antibodies that bind the 
antigen, or the antigen can be directly absorbed to the surface. Then antibodies 
conjugated with enzymes are added to form an antibody-antigen complex. The 
enzymes are able to convert the next substance added into a fluorescent signal. This is 
roughly the procedure of the ELISA. In another antigen detection method, 
immunofluorescence (IF), the localization of virus proteins to different parts of the cell 
increases the specificity [65].  
 
Serology has a limited function on the acute phase of a viral infection. Increased levels 
of IgM suggest acute infection, but normally a substantial increase of IgG is required in 
order to confirm the infection. The second examine of the serum are preferably made 1-
2 weeks after the acute one, which makes the turn-around time too long for many 
clinical purposes. However, it still plays an important role in some settings. For 
example in the hematological field, screening of antibodies reveals knowledge about 
latent viruses, such as herpes viruses, and hepatitis B virus which could reactivate after 
immunosuppressive treatment. In immunosuppressed patients, however, serology is of 
limited use as they may have insufficient ability to mount a humoral response and may 
have received antibodies passively through transfusions. Furthermore, for screening of 
blood donors and diagnosis of viral hepatitis and HIV, serology is a useful tool [65]. 
 
 
2.4.2 Polymerase chain reaction 
 
Sensitivity in detection of viruses has increased considerably with nucleic acid 
amplification tests. Less than ten years after Kary Mullis and his colleagues described a 
specific enzymatic amplification of DNA in vitro [66], he was awarded with the Nobel 
Prize in Chemistry in 1993 in Stockholm. Ever since, this method have been improved 
in order to be faster and less labor-intense. Furthermore, it has been improved to be able 
to estimate the number of viral (genome) copies in the sample. The real-time PCR 
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described below has of course its base in Mullis’ method described in 1986. The major 
ingredients in a real-time PCR are: 
 
1. The template (in this case the viral genome) 
2. DNA building blocks (free nucleotides; dNTPs) 
3. A heat stable polymerase (in this thesis, the Taq polymerase) which thrives in 
70°C [67] 
4. Primers (forward and reverse) complementary to the specific DNA region of 
interest 
5. The probe which is a single stranded oligonucleotide designed to be 
complementary to a spot between the forward and reverse primers’ binding 
sites). Therefore only specific PCR product can generate fluorescent signal in 
TaqMan PCR. The probe has a fluorescent reporter dye in its 5’ end and a 
quencher in its 3’ end. The quencher inhibits the reporter until the polymerase 
cleaves the probe. 
6. Buffer solutions and magnesium in order to create an optimal environment for 
the polymerase 
 
The ingredients above are mixed in certain concentrations and then the major steps in 
the reaction are: 
 
1. Denaturation: Heating the sample/mixture to 95°C in order to denature double 
stranded DNA (dsDNA) to single stranded DNA (ssDNA). This makes the 
target region of the viral genome available for the primers and the probe 
2. Hybridization: A lowering of the temperature to ~60°C facilitates the primers 
and probe binding to the viral genome 
3. Elongation: Raising of the temperature to 70-80°C, the optimal working 
temperature for the polymerase. In this step new copies are produced and for 
each copy, a signal is detected (Figure 2) 
4. The steps above are repeated for 40-50 cycles (as the polymerase is heat stable, 
new enzymes after each cycle are not required). 
 
Not all viruses have a genome consisting of DNA. In fact, most of the respiratory 
viruses have their genes stored in RNA molecules. As the polymerase mentioned above 
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only can elongate ssDNA, the RNA has to be converted by a reverse transcriptase (RT) 
into a complementary DNA (cDNA) before real-time PCR. This is made together with 
random hexamer oligoprimers, and the viral genome (or actually the complementary 
sequence) of interest can subsequently be amplified using the PCR scheme above. This 
method is sometimes called RT-PCR which could be misunderstood as real-time PCR. 
Numerous different abbreviations are used, but for the experienced reader this is 
however seldom a problem. 
 
 
 
 
 
Figure 2. The annealing of primers and probe, elongation by means of polymerase, and 
the subsequent release of the reporter dye from the quencher as the genome is copied.  
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2.5 THE VIRUSES 
 
Viruses are found wherever there is life and have probably existed since living cells 
first evolved [1]. They are the smallest biological units that can infect living organisms. 
Somewhat unfair, viruses are defined not to be a living form. This is simply due to their 
lack of own metabolism; they must invade living cells and use their hosts’ machinery in 
order to replicate. Viruses consist of two or three parts: the genetic material (DNA or 
RNA), a protein coat (capsid) that protects these genes, and in some cases an envelope 
of a lipid bilayer that surrounds the protein coat when they are outside a cell. However, 
the shape and size of different viruses vary greatly. An overview of the viruses 
mentioned in this book is outlined in Figure 3 based on the Baltimore classification. 
Most of them are normally referred to as respiratory viruses as they cause disease in, or 
at least are initially transmitted via, the respiratory tract. The viruses’ role in both 
immunocompetent and certain immunocompromised cohorts is discussed below. In 
particular, their potential as etiological agents to fever is penetrated. 
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Figure 3. The viruses discussed in this thesis grouped according to the Baltimore 
classification. The classification is based on the method of viral mRNA synthesis. The 
viruses presented in group I usually must enter the host nucleus before it is able to 
replicate. Some of these viruses require host cell polymerases to replicate their 
genome, while others, such as adenoviruses or herpes viruses, encode their own 
replication factors. Parvovirus in group II replicates within the nucleus, and form a 
double stranded DNA intermediate during replication. The DNA viruses are dependent 
on the cell cycle. The genome of viruses in group IV cannot be directly accessed by host 
ribosomes to immediately form proteins. Replication in positive-strand RNA viruses is 
thus via a negative-strand intermediate. The genome of viruses in group V, however, 
can directly be used by the host cell’s machinery in order to replicate.  The RNA 
viruses replicate primarily in the cytoplasm and are not dependent on the cell cycle as 
the DNA viruses. 
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2.5.1 Respiratory syncytial virus 
 
Beside influenza virus, the respiratory syncytial virus (RSV) is probably the most well-
known virus for parents of small children. This virus is namely the most common cause 
of lower respiratory tract infections in infants and young children [68, 69], and 
serological data show that almost all children have been infected before two years of 
age [70]. Its seasonal variability [71] is reflected by the high pressure on the pediatric 
health care infrastructure during the winter and early spring! RSV is highly contagious 
and re-infection can occur at any point later in life. Then it normally causes milder 
symptoms similar to those caused by “common cold” viruses [70]. However, in adults, 
foremost elderly, the virus can cause severe disease [72, 73]. RSV is rather pyrogenic 
but upper respiratory tract infections (URTI) can present with our without fever. Fever 
is, however, highly associated to lower respiratory tract infections (LRTI) due to RSV 
[74]. 
 
 This virus has been shown to cause severe LRTI with a high mortality rate in HSCT 
recipients [75, 76]. Transplanted patients typically present with fever and upper 
respiratory tract symptoms (URTS) followed by more severe symptoms as LRTI 
develops [77, 78]. Studies have shown a cumulative incidence ranging across 0.4-1.5% 
and 3.5-8.8% in autologous and allogeneic HSCT recipients, respectively [79-81]. In 
patients with hematological malignancies or HSCT recipients with RSV infection, 
progression to LRTI was associated with at least two independent risk factors: high age 
and absence of RSV treatment [82]. This is an interesting finding as reviews of 
randomized trials have concluded ribavirin not being effective in the treatment of LRTI 
caused by RSV [83, 84]. 
 
 
2.5.2 Metapneumovirus 
 
The human metapneumovirus (HMPV) is a recently discovered RNA virus [85] that 
has been shown to cause both URTI and LRTI [86]. The virus is closely related to RSV 
but have two major genomic differences; the gene order differs and HMPV lack two 
non-structural genes that are thought to encode proteins with an anti-interferon activity 
[87]. However, it is unknown how the absence of these proteins affects HMPV 
pathogenesis. Nearly all children have been infected with HMPV during their first five 
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years in life [85, 88]. HMPV is thus a major pediatric pathogen and is the second 
commonest cause of bronchiolitis next to RSV [89, 90]. In temperate climates, the 
incidence of the virus is increased during the late winter to early spring and is 
responsible for a significant proportion of URTI and LRTI across all age groups in both 
healthy and immunocompromised hosts worldwide [91]. HMPV, like RSV, do not 
appear to cause asymptomatic carriage in the respiratory tract of healthy individuals 
[85, 89, 92, 93]. URTI due to HMPV can present with or without fever [94] whereas 
LRTI is recently summarized to be highly associated to fever [74].   
 
URTI with HMPV can progress to severe LRTI and death in both pediatric and adult 
hematological patients [95-98]. The virus was isolated from bronchoalveolar lavage 
(BAL) in 26% of symptomatic HSCT recipients and carried a mortality rate of 80% 
[98]. Beside URTS, the infections were initially characterized by fever before the 
development of severe LRTI. However, in this patient category, prolonged 
asymptomatic infection has been described [99]. As for RSV, there is no consensus of 
the effectiveness of treatment with ribavirin. However, it has been demonstrated to 
decrease replication of the virus in a mouse model [100] as well as being successful 
when administrated intravenously in lung transplant recipients [101]. 
 
 
2.5.3 Rhinovirus 
 
The human rhinovirus (HRV) was first described in 1956 [102] and is today known as 
the major cause of respiratory tract illness [103, 104]. The two species first discovered, 
A and B, cause rather mild symptoms, the common cold, whereas the recently 
discovered human rhinovirus C [103, 105, 106] is suggested to cause more severe 
symptoms [103]. HRV infections occur year round with seasonal peaks of incidence in 
the early fall and spring [107-110]. Infections with HRV are commonly associated with 
rhinorrhea, sore throat, nasal congestion, sneezing, cough, and headache [111]. Less 
often malaise, chills, and low-grade fever occur [104]. The most exciting hypothesis 
was recently presented, namely that HRV epidemics could interfere with the spread of 
influenza virus [112]. This is however yet to be confirmed. 
 
HRV have been described as causative pathogens of LRTI in immunocompromised 
patients [113, 114], either as the sole pathogen or as a co-pathogen with bacteria or 
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other respiratory viruses. However, two studies that prospectively investigated the 
incidence of respiratory virus infections in patients with hematological cancer observed 
no or only a very low number of HRV infections in cases with respiratory symptoms 
[81, 115]. Results from another study indicated that when detected at high viral load, 
HRV may cause severe URTI and LRTI, whereas when detected at a medium-low viral 
load (an event more frequent in immunocompromised subjects), they may represent 
only bystander viruses [116]. Yet another study found HRV to be the predominant 
respiratory virus associated with URTI but none of the patients had progression to 
LRTI, and all patients recovered completely [117]. The disparity of reported incidences 
could partly be explained by the difficulties of to detect the virus; it is rather hard to 
culture, and a PCR must be thoroughly designed to cover the great diversity of 
genotypes. 
 
 
2.5.4 Enterovirus 
 
In this text human enterovirus (HEV) is represented by the non-polio enteroviruses; 
coxackievirus, echovirus, and other enteroviruses. Poliovirus is also an enterovirus but 
is excluded here. All HEV are closely genetically related to HRV and since they share 
biological features and probably have a similar pathogenetic effect in humans, it has 
recently been proposed an inclusion of HEV and HRV in the same subset within the 
Picornaviridae family [118]. The viruses replicate in lymphoid tissue in the pharynx 
and in the small intestine but in about 5% of cases the virus may spread to other tissues; 
central nervous system, myo- and pericardium, striated muscles, and skin. The most 
frequent symptoms are thus fever, sometimes accompanied by a rash or mild URTS. In 
the cases of viral spread to other organs, more severe syndromes can occur; aseptic 
meningitis, perimyocarditis, myalgia (Bornholm disease), herpangina and the Hand, 
Foot and Mouth disease [119]. All these syndromes include fever in the panorama of 
symptoms. 
 
HEV infections in immunosuppressed individuals are not widely investigated, but some 
studies are performed on allo-HSCT recipient. Chakrabarti et al reported that 10% of 
recipients of T-cell depleted grafts developed HEV infections post transplant, but only 
four episodes were associated with symptomatic illnesses attributable to HEV [120]. 
Furthermore, there was no mortality directly related to HEV. In contrast, in four HSCT 
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recipients with acute respiratory illness, HEV was isolated as the sole pathogen in 
BAL. All infections progressed to severe pneumonia where three were fatal [121]. Yet 
another group observed HEV infections in three pediatric allo-HSCT patients, who 
received UCB. Two died from the infection [122]. In a 2-year prospective study on 130 
hematological transplanted and non-transplanted patients HEV represented 5% of 
respiratory viral infections [115]. LRTI was present in one third of the episodes. 
Unfortunately, none of the reports above have investigated fever associated to HEV 
infection. 
 
 
2.5.5 Coronavirus 
 
If excluding the human corona virus (HCoV) that caused the global epidemic of severe 
acute respiratory syndrome (SARS) in the beginning of this century [123, 124], this 
group of viruses cause rather harmless URTS [125]. After HRV these viruses play the 
major role in causing common colds [107], and all HCoV show a seasonal variability in 
temperate climate countries with frequent transmission and detection during the winter 
[126, 127]. One of the strains is also associated with croup (acute 
laryngotracheobronchitis) [128], a disease foremost associated with parainfluenza virus 
(PIV) type 1 [129]. Two strains of HCoV were first described in the 1960s [130, 131] 
but as a consequence of an increased interest for this group of viruses after the SARS 
epidemic, two new viruses, NL63 and HKU1, were recently discovered by groups in 
the Netherlands and Hong Kong, respectively [132, 133]. Nicely summarized by van 
der Hoek, fever is reported to be present in 50-70% of the cases of infection with these 
two new strains [134]. This was not the situation for HCoV-OC45 and HCoV-229E 
where less than one out of five volunteers inoculated by the virus developed fever [125, 
131]. 
 
In parallel to other respiratory viruses, HCoV have been subject to investigations of 
their role as disease-causing pathogens in immunocompromised patients. HCoV have 
recently been associated with severe LRTI in lung and liver transplant recipients [135] 
and HCoV-229E has been isolated from HSCT recipients with fever and cough [136]. 
In another study on five children with ALL and one pediatric renal transplant recipient, 
HCoV was the sole respiratory pathogen detected. The ALL patients presented with 
fever alone or together with various URTS. 
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2.5.6 Influenzavirus 
 
Probably no other respiratory virus is as well known and discussed as the 
influenzavirus. Every year, the name of the virus is literarily on everybody’s lips before 
the nasopharynx is infected by the actual virus! Although it was not discovered until 
1933 [137], epidemics of the virus have been described several times far back in the 
history. Although influenza type C can be severe and can cause local epidemics, the 
species is rare compared to types A or B. Only type A and B are thus discussed below. 
The influenza virus A show great genetic and antigenic variability which arise from 
two different mechanisms: (1) the antigenic drift caused by the lack of proofreading 
and reparation of the genome during replication; (2) the antigenic shift that occurs 
when two different influenza viruses infect the same cell and assort their segmented 
RNA. The impact of the changed genome is, as the names of the mechanisms indicate, 
dependent on a change of the virus’ phenotype. Not surprisingly, epidemics and 
pandemics are more likely to occur after an antigenic shift where a new strain with a 
new combination of the important proteins hemagglutinin (H) and neuramidase (N) 
may have been developed. Influenza viruses A and B appear in all age groups but have 
most impact in the elderly [138]. This is due to a higher risk for them to suffering from 
a secondary bacterial pneumonia in the convalescent period [139]. Although the 
influenza virus B cause milder symptoms than does influenza virus A, the disease is 
rather similar; rapid onset of fever, malaise, muscle pain, and cough. 
 
Several studies have demonstrated infections with either influenza virus A or B in 
transplanted patients, but no difference in clinical presentation and outcome is 
determined [140-142]. The mean duration of shedding is longer for allo-HSCT 
recipients who are not given influenza antiviral treatment; 11 days, which is out of the 
range for immunocompetent individuals (5-10 days) [143]. A much longer period of 
shedding (>1 year!) was reported in an immunocompromised patient infected with a 
multidrug-resistant influenza A virus [144]. Furthermore, with only seven positive 
cases in allo-HSCT recipients, Peck and colleagues reported afebrile presentation in 
five of them, and absence of myalgia in all cases [145]. In contrast, in a prospective 
study on adult leukemia patients undergoing remission-induction chemotherapy, all 
influenza positive patients presented with fever, rhinorrhea, nasal congestion, headache, 
and myalgia [146]. Furthermore, in a similar cohort, influenza virus was associated 
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with fever in 87% of the cases [147]. Severe lymphopenia is identified to be an 
independent risk factor for progression to LRTI [82]. 
 
 
2.5.7 Parainfluenza virus 
 
These viruses resembled the influenza viruses but were not related to them 
antigenically; hence parainfluenza virus. There are four subtypes of the virus [148, 
149] named PIV 1-4. Although severe infections with PIV 4 have been reported [150, 
151], the role of this subtype as a potential pathogen is still unclear [129]. Therefore, 
PIV refer to PIV 1-3 in the text below. PIV can cause both URTI and LRTI. As 
mentioned above, the virus is associated with croup in small children but can also cause 
the same clinical syndrome in adults [129]. PIV have, however, been associated with 
every kind of upper and lower respiratory tract illness, and there is a strong relationship 
between PIV and specific clinical syndromes such as bronchiolitis, pneumonia, and 
tracheobronchitis; all associated with fever. Even though they cause primary infections 
early in childhood, the immunity generated is not long-lasting and re-infections are 
therefore common [129]. Epidemiologically, PIV 1 and PIV 2 peak during the fall and 
winter, whereas PIV 3 peaks during the spring and summer [129, 152]. 
 
Immunocompromised children and adults appear to be particularly susceptible to 
developing severe and fatal LRTI with PIV. Significant disease, including respiratory 
failure and death, has been reported in solid organ transplant recipients, presenting with 
cough, dyspnea, and fever [153]. Giant cell pneumonia caused by parainfluenza type 3 
was present in a patient with acute myelomonocytic leukemia [154] and all types is a 
common cause of respiratory illness or even death after HSCT [155-158]. In a Chilean 
prospective study they found PIV in 13% of the episodes of febrile neutropenia 
occurring in pediatric cancer patients [159], and in a retrospective study on adult 
leukemia patients with respiratory tract symptoms, two thirds presented with fever 
[160]. In a Finnish study on PIV 3 in hematological patients (transplanted and non-
transplanted), all positive cases were associated with fever together with cough or 
rhinorrhea. Infiltration on chest radiograph was a frequent finding [161]. 
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2.5.8 Adenovirus 
 
The great variety of symptoms caused by this DNA virus is reflected by its number of 
serotypes. Since its discovery in 1953 [162-164], at least 55 different serotypes are 
described causing a broad range of infections such as respiratory, gastrointestinal, and 
conjunctival in both the immunocompetent and immunocompromised host [165-168] 
(Table 2). In contrast to other respiratory viruses, the incubation time for adenovirus 
(AdV) is rather long, 5-10 days, and its ability to survive outside its host is impressive. 
This is illustrated by outbreaks of conjunctivitis in swimming pool areas where the 
transmission of the virus thus are water-borne [169]. AdV is also a common cause of 
tonsillitis and fever in children [170]. Worldwide, the AdV is a common cause of 
gastroenteritis with high mortality in children in developing countries [171]. 
 
 
Table 2. Association of adenoviral diseases and principal serotypes in 
immunocompetent and immunocompromised individuals 
Syndrome Serotypes in species A B C D E F 
Upper respiratory illness  All All    
Lower respiratory illness  3, 7, 21   4  
Pertussis syndrome   5    
Acute respiratory disease  7, 14, 21, 55   4  
Conjunctivitis  3, 7, 11 1, 2 8, 19, 37, 53, 54 4  
Gastroenteritis      40, 41 
Hemorrhagic cystitis  7, 11, 34, 35     
Hepatitis  3, 7 1, 2, 5    
Myocarditis  7, 21     
Meningoencephalitis  7 2, 5    
Venereal disease   2    
Disseminated disease 31 11, 34, 35 1, 2, 5   40 
NOTE. AdV 53 and 54 should be referred to as “types” rather than serotypes. The table 
is a summary of data derived from three recent publications [165-168]. 
 
 
 
AdV infections are self-limited in the immunocompetent host. This is not always the 
case in severely immunocompromised patients such as HSCT recipients, where clinical 
manifestations including pneumonia, hepatitis, hemorrhagic cystitis, colitis, 
pancreatitis, meningoencephalitis, and disseminated disease are described [172-179]. 
The incidence after HCST varies with the patients’ risk factors, but could be dependent 
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on other factors such as number of body sites investigated and choice of detection 
method. Most risk factors are in some way associated with the grade and duration of 
immunosuppression; slow lymphocyte recovery [180, 181], usage of T cell-depleted or 
CD34+ selected grafts [180-183], grafts from an unrelated donor [184], and GVHD or 
its therapy [185]. Furthermore, children are at higher risk for acquisition of AdV 
infection post HSCT [174, 183, 184, 186].  
 
No antiviral drugs are developed specifically against AdV, although drugs as ribavirin 
and cidofovir have been used [187, 188]. Of these two, cidofovir are the most 
commonly used but have severe and sometimes unacceptable side-effects; foremost 
renal [166]. Fortunately, children tolerate the drug better and with preemptive 
rehydration and a reduced dose, cidofovir have been described to be a safe alternative 
to withdrawal of the immunosuppressive treatment or expectation [189]. Feuchtinger 
and colleagues tried the more spectacular option to use virus-specific donor T cells for 
adoptive transfer of immunity to nine pediatric HSCT recipients with systemic AdV 
infection [190]. They concluded that the strategy was feasible and effective. 
 
The importance of early detection of AdV infection in the post transplant period has 
highlighted the difficulties of the development of a proper diagnostic tool. Virus 
isolation may be too slow for clinical use, whereas PCR are fast and very sensitive. 
However, the PCR assay is only sensitive if it is designed to cover the specific serotype 
causing the infection. Many groups have put effort in developing a PCR assay that 
covers all known AdV serotypes; a demanding but exciting challenge [182, 191-194]. 
 
 
2.5.9 BK virus 
 
This polyomavirus is a small, non-enveloped DNA virus. The name BK virus (BKV) is 
the initials of the patient from whom it was first isolated [195]. It is genetically closely 
related to another polyomavirus, JC virus, also discovered in 1971 [196]. Primary 
infection, typically asymptomatic, occurs during childhood and is followed usually by a 
lifelong phase of latency in immunocompetent subjects. 
 
Upon immunosuppression, however, the latent infection may be reactivated even when 
high levels of serum antibodies are present. Its potential to cause harm in the urinary 
   31 
tract was first reported in 1983 [197] but the emergence of the virus as a disease-
causing agent in renal transplant patients began later in the mid-1990s [198]. BKV-
associated hemorrhagic cystitis (BKHC) is a potentially serious complication that 
frequently occurs in recipients of allogeneic HSCT recipients [199, 200]. Clinical 
manifestations of BKHC can be minor with asymptomatic hematuria, or severe with 
massive blood loss, pain, urinary obstruction, renal failure and even death [201-203]. 
The virus’ association to fever in this patient category is to my knowledge not 
investigated. Recently, however, a non-transplanted patient with peripheral T-cell 
lymphoma, developed acute renal failure which was associated with systemic BKV 
activation, and the initial symptoms were fever and urinary frequency [204]. 
 
 
2.5.10 Epstein-Barr virus 
 
The Epstein-Barr virus (EBV) is a herpes virus that was first described in 1964 [205]. It 
infects via saliva, replicates in epithelial cells in the pharynx, and then later primarily in 
the B cells where lifelong latency is established [206, 207]. In most cases, a primary 
infection occurs during the first years of life and is asymptomatic or causes symptoms 
indistinguishable from other viral respiratory infections. However, if it occurs later in 
life, the immunological response is more powerful and causes a disease with several 
names; glandular fever (enlarged lymph nodes), mononucleosis (atypical lymphocytes 
resembling monocytes seen in the microscope) or kissing disease (infection requires 
exchange of rather high amount of saliva). Whereas the local symptom is tonsillitis, the 
systemic symptoms are fever, fatigue, lymphadenopathy, and splenomegaly. Liver 
enzymes are normally elevated and sometimes hepatitis develops. There may be a 
prolonged convalescence with tiredness and low-grade fever for months. Although the 
virus is not very contagious and requires close contact in order be transmitted, nearly all 
adults have been infected with EBV. The virus is associated with several malignancies 
such as different lymphomas [208]. 
 
In the healthy individual, the EBV infection is controlled by humoral and T-cell 
mediated immune responses. However, reactivation of EBV is frequent in 
immunocompromised patients [209-211], and EBV-associated lymphoproliferative 
disease (EBV-LPD) after allogeneic HSCT is a common complication. EBV-LPD is 
caused by the proliferation of EBV-infected B cells, and once it develops, it rapidly 
 32 
progresses and is sometimes fatal. It can present with varying clinical signs and 
symptoms; fever, mononucleosis-like illness with fever, pancytopenia, 
lymphadenopathy, and even rapidly progressive lymphoma [212, 213]. 
 
 
2.5.11 Cytomegalovirus 
 
The name of cytomegalovirus (CMV) refers to the size of the infected cells, which 
contain large intranuclear inclusions. Following primary infection the virus establishes 
latency in lymphocytes and possibly endothelial cells from which it may be reactivated. 
CMV is a threat even before we are borne. It can cause congenital infection upon 
primary and reactivated maternal infection. The infant will have a generalized infection 
at birth, but clinical symptoms are present in only 5-10% of the cases. Although the 
fetal infection may show minimal manifestations at birth, it can cause severe 
complications later in life, especially in the central nervous system [214]. CMV can 
also cause perinatal infection via cervix secretion or via breast milk, but in most cases it 
is subclinical [215]. Later in life the infection usually is subclinical but can cause a 
symptom pattern rather similar to mononucleosis. The disease is characterized by 
protracted fever, malaise, myalgia, and liver function abnormalities.        
 
As for many other herpes viruses, CMV is commonly reactivated upon severe 
immunosuppression. Despite several new prophylactic options for CMV infection, the 
virus is still one of the major causes of morbidity and mortality after allo-HSCT where 
it causes pneumonia, gastroenteritis, and less commonly retinitis and hepatitis [216]. 
The disease can develop both early and late after the transplantation procedure [217]. 
Risk factors for CMV infection post HSCT are seropositivity of the recipient [218, 219] 
and, as for AdV infection, acute GVHD [220, 221]. In some situations, grafts from 
seronegative donors increased the risk for complications [222]. Usage of a T cell-
depleted graft or a graft from a HLA-mismatched donor further increases the risk in 
seropositive recipients. In addition to direct morbidity and mortality, CMV is 
associated with opportunistic infection [223-225]. 
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2.5.12 Parvovirus B19 
 
This first member of the parvoviridae family that can cause infection in human was 
discovered in 1974, and the name refers to its small size and the sample 19 in panel B 
in which it was found [226]. However, it is a great survivor and is distributed over the 
globe infecting almost all people at some point during their lives [227]. The incidence 
of infection shows a seasonal variation in temperate climates, being more common 
during winter and early spring. Parvovirus B19 (B19) is transmitted through the 
respiratory route, but can also be transmitted through bone marrow and organ 
transplantations, and via transfused blood products [228, 229]. The pregnant woman 
can also infect vertically to the fetus, which is associated with several serious 
complications to the fetus, including fetal death [230]. One disease associated with the 
virus is erythema infectiosum (or fifth disease, or slapped cheek syndrome) that mostly 
occur in children aged 5-15 years. Intranasal inoculation of B19 in healthy volunteers 
revealed a biphasic clinical course with mild symptoms of fever, malaise, myalgia, and 
itching in the first peak (8-9 days post inoculation). After 15-17 days, maculopapular 
rash occurred alone or together with arthralgia [231, 232]. Although B19 viremia is 
rather infrequent in the healthy population and a large proportion of adults have 
acquired virus specific antibodies [229, 233-237], asymptomatic infections with B19 
are present in 25-50% of cases [238, 239]. In bone marrow, however, B19 DNA is 
found in 2% of healthy individuals and in up to 15% of children with hematological 
malignancies without concomitant viremia [240-243]. B19 replicates in erythroid 
precursors and by that inhibit the erythropoesis [244, 245]. During the time of the first 
peak of symptoms, the bone marrow has completely lost its erythroid precursors. 
 
The immunocompromised host present a different clinical picture with mild or absent 
immune mediated symptoms such as rash [246]. Furthermore, persistent B19 infection 
can cause severe chronic anemia. Treatment with plasma containing specific antibodies 
against B19 resulted in decreased serum levels of the virus, the appearance of 
reticulocytes, and interestingly, symptoms of the fifth disease! The infection can also 
indirectly harm the immunocompromised patient; one recent study showed that B19 in 
children with ALL is associated with cytopenia resulting in prolonged interruptions of 
chemotherapy [240]. Here only one out of seven experienced symptoms as the classical 
rash, whereas six of them were febrile. 
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2.6 INFECTIONS IN IMMUNOCOMPROMISED PATIENTS 
 
The anticancer treatments can affect the immune system in a variety of ways. The very 
first line of defense is altered by breakdown of mucocutaneous barriers by for example 
surgical removal of the primary or metastatic lesions, radiation therapy, GVHD, 
mucositis, but also the cancer itself by local tumor invasion. Furthermore, indwelling 
surgical devices such as central venous or urinary catheters increase the risk for 
infections [247]. Both in a quantitative and qualitative manner, chemotherapy has a 
negative effect on the next line of the non-specific defense, the phagocytic cells. This 
dramatically increases the risk of infection which is illustrated by the direct relationship 
between risk of infection and severity, duration, and rate of decline of neutropenia 
(most frequently defined as an absolute neutrophil count <0.5×109cells/L or 
<1.0×109cells/L and expected to fall) [248]. Neutropenia is therefore the most 
frequently used marker for immunosuppression in the cohorts discussed below. 
However, isolated neutropenia is a rare event associated with certain conditions such as 
Kostmann disease, and thus many of the infections, for example viral, are associated 
with the parallel decline of lymphocytes. The B and T cells that are responsible for 
regulating the specific humoral and cell-mediated response, respectively, are also 
impaired quantitatively and qualitatively by malignancies and its treatment. The altered 
immunoglobulin production of the B (plasma) cells increases the risk for bacterial, 
fungal, and viral infections. Furthermore, impaired cellular response is associated with 
major risk of acquiring viral, fungal, and intracellular bacterial infections [247]. 
Splenectomy is a part of some treatment strategies and is associated with an increased 
risk for sepsis with encapsulated bacteria. 
 
 
2.6.1 Post allogeneic hematopoietic stem cell transplantation 
 
Allo-HSCT recipients are at risk of certain infections in different periods after 
transplantation. The timing of immune reconstitution determines the timing of these 
infections. Immune system recovery for HSCT recipients takes place in three phases 
beginning at the day of transplantation. Before engraftment (<30 days after HSCT) 
HSCT recipients have two critical risk factors for infection; prolonged neutropenia and 
altered physical barrier resulting from the conditioning regimen and frequent vascular 
access required for patient care. During this phase, the infectious complications of 
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HSCT patients are not very different from those encountered in other profoundly 
neutropenic patients such as acute leukemia patients. Consequently, the normal oral, 
gastro-intestinal, and skin flora are sources of infection. Candida, but also, upon 
prolonged neutropenia, Aspergillus are common infections [249, 250]. Viral infections, 
especially herpes simplex virus (HSV), are frequent [251], but the infection-related 
morbidity and mortality at this time is mainly due to severe bacterial sepsis, 
pneumonia, and fungal infections [39, 252-254]. After engraftment, other herpes 
viruses and adenovirus are critical pathogens [210, 220, 255-258]. In this period, CMV 
causes pneumonia, hepatitis, and colitis and potentates super infection with 
opportunistic pathogens, particularly among patients with active GVHD. Other 
dominant pathogens during this phase include Pneumocystis jirovecii and Aspergillus 
species [259-261]. After 6 months, due to cell-mediated and humoral immunity defects 
as well as impaired reticuloendothelial system function, allo-HSCT recipients are at 
risk for infections that include CMV, Varicella-Zoster virus (VZV), EBV, respiratory 
viruses, and infections with encapsulated bacteria [262-265]. 
 
The viral contribution to post HSCT complication is thus substantial. The strategy of 
monitoring CMV and the use of preemptive treatment in this period is a successful 
story [220, 266-272] and since AdV have emerged as an important pathogen [179, 273-
280] a similar screening for AdV could be of clinical benefit. Our investigation of such 
a strategy is described in Paper I. 
 
 
2.6.2 Patients with febrile neutropenia 
 
Chemotherapy-induced neutropenia is one of the major side effects of cancer treatment. 
The risk of infection is increased by the severity and duration of neutropenia [248, 
281]. Due to an impaired inflammatory response, signs of inflammation such as local 
heat, swelling, exudates, fluctuation and ulceration are often diminished. Fever is thus 
often the first and sometimes only sign of infection [282, 283]. The approach of 
empirically administrated parental broad-spectrum antibiotics has substantially 
decreased the mortality rates due to infections in these patients [284-287], but even 
though the fever might be the result of bloodstream bacterial infections, 70–90% of the 
episodes have no causative micro-organisms demonstrated in their blood cultures [288-
303]. It can thus be hypothesized that many episodes of febrile neutropenia can be the 
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result of inflammatory responses to for example transfusions of blood products, 
malignancy itself, chemotherapeutic drugs, mucosal damage, or – viral infections. The 
inpatient management using broad-spectrum antibiotics is associated with disruption of 
family life, nosocomial complications, increased resistance to antibiotics, and high 
medical costs. As a result, several attempts have been made to identify patients at low 
risk for bacteremia or serious complications [304-315]. 
 
Since research and routine diagnostics have focused primarily on the bacterial 
contribution to fever, we have a fairly good knowledge about this part of the spectrum. 
The proportion of Gram-positive and Gram-negative bacteria found, have fluctuated in 
some parts of the world during the last decades. The main theoretical explanations for 
this are the use of antibiotic prophylaxis and central venous catheters, as well as 
emergence of resistant bacteria [316, 317]. 
 
As described for each virus in the previous sections, viral infections are common in 
many settings of immunocompromised patients. However, the viruses’ role in febrile 
neutropenia in hematological patients (not being subjects for allo-HSCT) is not 
thoroughly explored. Two studies are described in paper II and IV that investigate 
viruses in the respiratory tract and blood, as potential etiological agents of febrile 
neutropenia. 
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3 AIMS 
 
The overall aim of this thesis was to investigate the frequency and clinical impact of a 
broad range of respiratory viruses in different cohorts of immunocompromised patients. 
The specific aims of each substudy are described below: 
 
 
I. To evaluate the clinical benefit of introducing screening for AdV in an already 
implemented surveillance program for CMV in pediatric and adult allo-HSCT 
recipients 
 
II. To investigate the prevalence of viruses in pediatric cancer patients with febrile 
neutropenia using both conventional viral detection methods and real-time PCR  
 
III. To determine the sensitivity of detecting respiratory viruses in adult 
hematological patients with febrile neutropenia using a flocked nasal swab in 
the outer part of the nasal cavity compared to nasopharyngeal aspirate 
 
IV. To investigate the prevalence of viruses in adult hematological patients with 
neutropenic fever, and to compare it to the prevalence of afebrile neutropenic 
patients. 
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4 PATIENTS, MATERIALS AND METHODS 
 
All studies on which this thesis is based have ethical permissions from The Ethical 
Review Board in Stockholm and Human Research Ethics Committee in Westmead 
(Sydney) where appropriate. Patients were eligible for enrollment after informed 
consent. Clinical and additional microbiological data were extracted from the patients’ 
medical records. 
  
 
4.1 PAPER I – ADENOVIRUS IN ALLOGENEIC HSCT RECIPIENTS 
 
4.1.1 The patients 
 
Between March 2006 and September 2007, a total of 20 pediatric and 77 adult 
recipients of allo-HSCT were recruited from two major Swedish transplantation centers 
at Karolinska University Hospital and Sahlgrenska University Hospital, respectively. 
The median age for the adults was 50 years (range 22-69 years) and for the children 12 
years (range 1.5-17 years). The predominant underlying diseases for the adults were 
acute leukemia (48%) and MDS (13%), whereas for the children non-malignancies and 
MDS were most common (45% and 25%, respectively). A similar proportion of 
recipients were prepared with MAC (generally cyclophosphamide ± busulfan) and RIC 
(generally fludarabine ± busulfan or cytarabine), respectively, and for the adults half 
were T cell depleted in vivo with either alemtuzumab or antithymocyte globulin. 
Fifteen (75%) of the children were T cell-depleted. The grafts used were in half of the 
cases from a matched unrelated donor (MUD), whereas an HLA-identical sibling could 
help 43% and 20 % of the adults and children, respectively. UCB was thus infrequently 
used in adults, but in one fifth of the children this strategy was assumed to be the best 
choice.  
 
 
 
4.1.2 Materials 
 
The recruited recipients were sampled before HSCT and then according to a 
surveillance scheme routinely used for detection of CMV; weekly during the first nine 
weeks and then after 3, 6, and 12 months. Peripheral blood was collected for analysis of 
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AdV in plasma. Peripheral blood mononuclear cells (PBMC) for detection of AdV-
specific T cells were collected from twelve randomly selected adult recipients at three 
time points; 4, 8 and 12 weeks after transplantation. 
   
 
 
4.1.3 Methods 
 
The real-time PCR assay used did include primers and probes earlier described [192] 
with an additional probe 5′FAM-TGCACCAGCCCGGGGCTCAGGTACTCCGA-
TAMRA3′ in order to minimize the nucleotide mismatch between the probe and the 
PCR amplicon derived from the AdV subgroup C [277]. 
 
An ELISPOT assay was used for analysis of AdV-specific T cells. In brief, the wells 
were coated with primary antibodies against human IFN-γ. The PBMC were stimulated 
by adenolysate, and biotinylated secondary antibodies and streptavidin-bound enzyme 
conjugate were added to bind to the primary antibody/ IFN-γ complexes. Finally, a 
colorimetric substrate was added and spots counted in an ELISPOT reader. 
 
Univariate analyses were performed using Fischer’s exact test for categorical data. 
Non-categorical variables were compared with the Mann-Whitney U-test. A multiple 
logistic regression model was created with Statistica version 8.0 (Windows) for 
multivariate analysis of risk factors for AdV infection. All tests were two-sided with a p 
value of <0.05 considered significant. 
 
 
4.2 PAPER II – VIRAL INFECTIONS IN CHILDREN WITH FEBRILE 
NEUTROPENIA 
 
4.2.1 The patients 
 
During one year (2007), a total of 90 episodes of febrile neutropenia occurring in 66 
children at the pediatric oncology units at the Children's Hospital at Westmead 
(Sydney, n=43) and Astrid Lindgren Children's Hospital at the Karolinska University 
Hospital (Stockholm, n=47), respectively, were analyzed with extended viral 
diagnostics. The median age was 5 years (range 5 months – 18 years) and non-solid 
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cancer types were slightly overrepresented (69%). In total, more than half of the 
children suffered from acute leukemia followed by neuroblastomas (10%) and 
sarcomas (7%).  
 
 
4.2.2 Materials 
 
Nasopharyngeal aspirate (NPA) and peripheral blood samples were collected in 
addition to samples for routine laboratory analyses. For detection of CMV, AdV, and 
EBV and B19, whole blood, plasma, and serum were used, respectively. 
 
 
4.2.3 Methods 
 
In NPA, conventional viral detection methods were used for detection of PIV, influenza 
A and B virus, RSV, HSV 1 and 2, VZV, HEV, AdV, and CMV. In addition, NPA was 
analyzed by real-time PCR for detection of RSV, influenza A and B virus, PIV, HEV, 
AdV, HRV, human bocavirus (HBoV), HMPV, non-SARS HCoV, and KI/WU 
polyomavirus [318, 319]. For detection of CMV, AdV, EBV, and B19 in blood, real-
time PCR was used [277, 320-322]. 
 
Group comparisons were performed by Kruskal-Wallis test using GraphPad Software. 
All tests were two-sided with p value of <0.05 considered significant. 
 
 
4.3 PAPER III – NASAL SWAB VERSUS NPA FOR VIRAL DETECTION 
 
4.3.1 The patients 
 
Independently of presence of URTS, a total of 98 episodes of febrile neutropenia 
occurring in 89 hematological patients were enrolled in this study. The median age was 
60 years (range 19-87 years) with acute leukemia and NHL as predominating 
underlying diseases.  The majority suffered from severe neutropenia, <100 
neutrophils/mm3. 
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4.3.2 Materials 
 
Paired samples of nasal and nasopharyngeal secretion were collected by a flocked nasal 
swab (fNS) and NPA, respectively.  
 
 
4.3.3 Methods 
 
First the fNS was inserted at least 20 mm and rotated inside each nostril, and then NPA 
was obtained via a sterile catheter inserted to the posterior nasopharynx (Figure 4). The 
fNS was transported without any medium, whereas the NPA was diluted with 2-3 mL 
of sodium chloride. Within the same day, a 500 μL of medium was added in which the 
fNS was shaken in order to release the biological material. 
 
 
 
Figure 4. Nasal swab versus nasopharyngeal aspirate for sampling of nasal and 
nasopharyngeal secretion, respectively. 
 
 
For both specimens, a real-time PCR assay including a broad panel of respiratory 
viruses covering AdV, HEV, HBoV, HCoV, HMPV, influenza A and B virus, PIV 1-3, 
HRV, RSV A and B was used [318]. 
 
Cohen’s kappa was calculated as a measure of agreement of the results obtained from 
either method. Wilcoxon signed-rank test and Pearson's correlation coefficient were 
used when appropriate. All tests were two-sided with p value of <0.05 considered 
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significant. The statistical software products InStat 3.05 and Prism 5.00 for Windows 
were used. 
  
 
4.4 PAPER IV – VIRUSES IN NEUTROPENIC ADULTS WITH AND 
WITHOUT FEVER 
 
4.4.1 The patients 
 
A proportion of the febrile episodes described in this paper were included in the study 
where we compared fNS and NPA (paper III). Between January 2008 and February 
2010 adult hematological patients presenting at Karolinska University Hospital, 
Stockholm, with neutropenia were included. In total, 144 of the episodes, occurring in 
124 patients, were associated with fever. A vast majority of these were included upon 
admission due to febrile neutropenia, whereas already hospitalized patients were 
included as soon as an elevated body temperature was measured. Another 39 patients 
(47 sampling occasions) were included upon regular clinical check-ups during 
neutropenia without fever. Patients admitted directly to the Intensive Care Unit where 
not included. Furthermore, patients having undergone allo-HSCT within the previous 
two years were excluded. The vast majority of the study subjects suffered from acute 
leukemia, NHL, multiple myeloma, or MDS. 
 
 
4.4.2 Materials 
 
At fever onset, the patients were admitted to hospital and sampled according to clinical 
routine. Bacterial cultures were performed on blood and in some cases from other 
locals such as urine, central venous catheter, feces, and pharynx. Within 72 hours, NPA 
and blood was collected for extended viral diagnostics. Whole blood and plasma were 
used for detection of CMV and AdV, respectively. For detection of EBV, B19, and 
BKV, serum was used. 
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4.4.3 Methods 
 
For detection of CMV, EBV, and AdV in blood, real-time PCR assays previously 
described were used [277, 320-322]. Newly developed primers and probes are 
described in Table 3, whereas for HRV (A and B) [323], HEV [324], influenza A virus 
[325], influenza B virus [318], RSV [326], and PIV 1 [327], the design is described 
elsewhere. 
 
For analysis of lymphocyte counts including subpopulations, peripheral blood was 
phenotypically characterized in 99 of the patients by staining with two sets of 
antibodies against the following cell surface markers; Set 1: CD3-FITC, CD8-PE, 
CD45-PerCP, CD4-APC; Set 2: CD3-FITC, CD16/CD56-PE, CD45-PerCP, CD19-
APC. TruCount tubes (BD Biosciences) were used for an absolute count. Thus, 
cytotoxic T cells, T helper cells, B cells, and NK cells were stained for. The size of 
monocyte populations was determined using the combination of side scatter and CD45. 
 
Univariate analyses were performed using Fischer’s exact test for categorical data. 
Non-categorical variables were compared with the Mann-Whitney U-test and also by 
Fischer’s exact test after dichotomizing the data above and below the median of both 
groups. Forward conditional binary logistic regression analyses were performed for 
multivariate analysis of factors associated with the dependent variable, fever. All tests 
were two-sided with p value of <0.05 considered significant. Software products used 
were Prism 5.00 for Windows and PASW Statistics 18. 
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Table 3. Newly designed primers and probes for different real-time PCR assays used 
in Study IV. 
Virus Primer/Probe Sequence (5’-3’) 
HCoV  FW YGATAAAGCTGTAGCTCGCAAACT 
ACGCGACCGTGCTGTAGC 
GATCATGAGATATCTGTTCAGAAGAAAATT 
CAGGGAATCATCTGTTCAAAAGAA 
REV GATTATCCAATTTACGAACCATGCTA 
GCTTGATTATCTAACTTACGCACCATACTA 
ACATATCCAAACGTCTTAACATTCCA 
AAACGTCGGAGCATGCCA 
PRO VIC-GATAAGAAGAGTAARGTTGTTTC-MGB 
VIC-TGGCTGAACAAGCTG-MGB 
 
HMPV  FW AAAGCATTAGGCTCATCCTCTACAG 
AAAGCTTTAGGCTCATCTTCAACAG 
AAAGCATTAGGCTCATCATCTACAGG 
REV ATTGTTAGATGACCTGGCAATGAC 
GTTGGATGACCTGGCAATGAC 
TGTTGGATGATCTGGCAATGAC 
TGTTGTTAGATGATCTGGCAATGAC 
TGTTAGATGACCTGGCGATGAC 
PRO NED-AGCAAAGCAGAAAGT-MGB 
 
Influenza B virus PROa 6FAM-CAGATCTGTGCAGTTGAG-MGB 
 
PIV2  FW TTACCTAAGTGATGGAATCAATCGC 
REV TCTTTYTCAGAYCTTGTAGCTACATAGCA 
PRO NED-AAGCTGTTCAGTCACTGC-MGB 
 
PIV3  FW TCCCCATGGACATTCATYGTT 
REV TGGCAYAGCAARTTACAATTAGGAA 
PRO NED-TGCCATGTCCATTTTA-MGB 
 
PIV4  FW CCAGTCAAATCAAYTGCCTCYG 
REV GATCTCTRATGCATAGTTCGCAAATT 
PRO NED-CATGTGGAAGATGTCC-MGB 
NOTE. HCoV, human coronavirus; FW, forward; REV, reverse; PRO, probe; HMPV, 
human metapneumovirus; PIV, parainfluenza virus. 
a Probe modified, otherwise as described by Tiveljung et al [318] 
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5 RESULTS AND DISCUSSION 
 
5.1 PAPER I – ADENOVIRUS IN ALLOGENEIC HSCT RECIPIENTS 
 
For all patients, including those who died before the follow-up period ended, a median 
of 11 samples (range 2–19) was collected weekly for AdV PCR directly after HSCT. A 
total of 5% (5/97) of the patients, three children and two adults, had at least one sample 
that tested positive for AdV DNA in plasma, although none of them had clinical 
evidence of AdV disease. This is in the lower part of the range of reported incidences 
illustrated in Figure 5 based on a summary made by Marcela Echavarría in 2008 [166]. 
The overall incidence is however 9% which is just slightly higher than the 5% reported 
in our study. One important difference however is the fact that not a single patient 
developed AdV disease, which is a conflicting result from the other studies where the 
AdV-associated morbidity and mortality of the infected was 10-89%. The disparity 
between the reports is most likely explained by differences in patient group 
composition with respect to known factors associated with AdV infection post allo-
HSCT (e.g. younger age and T-cell depletion). Moreover, not all relevant publications, 
such as the classical publication by Lion et al from 2003 [328], were taken into 
consideration. They found an AdV incidence of 27% in pediatric allo-HSCT recipients 
and stated that PCR-based monitoring of AdV in peripheral blood permitted early 
diagnosis of disseminated disease. Except for enteritis in some patients with AdV 
positivity in stool, detection of the virus at sites other than peripheral blood was not 
associated with AdV disease. Interesting of this, the same group recently presented data 
suggesting that detection of AdV in stool permits early detection of impending invasive 
AdV infection [329]. The incidence of AdV infection in children was 15% in our study. 
A rather similar overall frequency (19%) has been reported (Figure 6). 
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Figure 5. Reported incidences of AdV in HSCT recipients between year 1976 and 2005. 
The pink column represents the incidence of AdV infection in our study. The dashed 
line represents the reported overall incidence. The number of included recipients is 
stated above each column. 
 
 
 
 
 
Figure 6. Reported incidences of AdV in pediatric HSCT recipients between year 1979 
and 2005. The pink column represents the incidence of AdV infection in children in our 
study. The dashed line represents the reported overall incidence in children. The 
number of included recipients is stated above each column. 
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The AdV titers in Patients no. 1-4 were below 1000 copies/mL plasma, but in the 
protracted AdV infection in Patient no. 5, the peak was 9000 copies/mL. Determination 
of serotype was possible in four of our AdV cases; serotype 1, 2, 3, and 31. Serotypes 1 
and 2 are very frequently isolated in HSCT recipients, reported in almost all studies 
where typing was performed. Serotypes 3 and 31 are reported in approximately half of 
the studies [166]. 
 
GVHD or its therapy is a known risk factor for AdV infection in allo-HSCT recipients 
[178]. In our study, all recipients suffered from GVHD at some time point during the 
follow-up period, but not necessarily before detection of AdV (Figure 7). GVHD was 
not found to increase the risk of acquiring AdV infection in our material.  
 
 
 
Figure 7. Sampling frequency of the AdV infected patients. AdV was found also in the 
intestine and kidneys at autopsy in Patient no. 3, and in feces at one occasion for 
Patient no. 5.  
 
Another known risk factor is younger age [174, 183, 184, 186]. The median age in the 
AdV positive group was 14 years (range 1.5-42) which was lower than 46 years (range 
2-69) in the AdV negative group (p<0.05; Figure 8). However, young age did not 
remain as a risk factor after multivariate analysis including possible confounding 
factors such as underlying disease, relationship to donor, stem cell source, conditioning 
regimen, and GVHD. 
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Figure 8. Difference in age between the AdV positive and AdV negative group.  
 
 
 
Other known risk factors are MAC, T-cell depletion, and the use of mismatched or 
unrelated donors [279, 328, 330-332], but those could not be confirmed in our study. 
However, MDS patients and recipients of bone marrow grafts were overrepresented in 
the group of AdV positive cases (p<0.01 and p<0.1, respectively). These associations 
remained after multivariate analyses with adjusted odds ratios (95% CI) of 56.2 (3.6-
876) and 15.7 (1.2-205), respectively. Previously, these factors have not been reported 
to be associated with higher risk of acquiring AdV infection. 
 
As discussed above, a number of factors influence the incidence of AdV infections in 
these patients. Two other factors may also contribute to the disparity, namely the 
number of body sites investigated and the viral detection methods used. However, such 
relationships could not be seen in a summary of the studies presented above (Figure 9). 
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Figure 9. Correlation of reported incidences to A) number of body sites investigated, 
and to B) viral detection method used. The pink dot in A represents our study. The 
dashed lines illustrate the 95% CI for the trend line.  
 
Rapid reconstitution of the lymphocyte population and, likely, the presence of AdV-
specific T cells of a donor origin, contribute to prevention of AdV infection early after 
SCT [190, 279, 332]. Our ELISPOT data showed that more than half of randomly 
selected adults had T-cell immune responses against AdV on at least one time point 
during the first 3 months. Unfortunately, only a low number of patients were tested, and 
none of them had AdV infection. Thus, the study could not determine the protective 
effect of the AdV-specific T cells. 
 
 
5.2 PAPER II – VIRAL INFECTIONS IN CHILDREN WITH FEBRILE 
NEUTROPENIA 
 
In paper I the aim was to identify a virus known to cause severe disease in a certain 
patient category. In paper II the aim is somewhat different. Here we try to identify a 
broad range of viruses as possible etiological agents of fever, not necessarily disease, in 
children with febrile neutropenia.  
 
Using conventional viral detection methods on NPA, together with bacterial culture on 
blood, a total of 26 out of the 90 febrile episodes (29%) revealed a possible etiological 
agent. Of these, bacteremia and one or more viral pathogens were identified in 21 and 
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10 episodes, respectively. Thus, with conventional methods, the viral prevalence was 
11%. Using the same samples for analysis by real-time PCR with an even broader 
range of detectable viruses (including CMV, EBV, AdV, and B19 in blood), one or 
more viral pathogens were detected in 44 of the cases (49%). Together with bacterial 
culture the total number of episodes with a microbial agent detected was 54 (60%; 
Table 4). This increase was due to an even more extended panel of viruses investigated, 
but also the switch to PCR explained additional findings; in a total of 22 samples a 
virus type that is detectable by conventional methods was detected by PCR. As many as 
71% of these were negative when IF and culture were used! 
 
Five out of eight patients with serial samples could demonstrate clearance after a 
median of 5.5 weeks (range 2.7-14 weeks), but as no sequencing was performed it is 
possible that the persistent virus actually was a new virus with another genotype. This 
has been shown to be a common event in a prospective study of infants [333]. 
Conflicting results are described regarding time of virus shedding in 
immunocompromised children. Despite no confirming sequencing, prolonged shedding 
of RSV and HRV was apparent in two studies on children with cancer [334, 335], 
whereas another study demonstrated clearance in 23 out of 27 cases of viral respiratory 
tract infection [336]. In the cases with prolonged shedding, HRV was present in three 
and RSV in one. Whether prolonged shedding occur or not, an important fact is that 
viral infections can be asymptomatic. Several recent studies have investigated the 
association between respiratory virus findings and symptoms in children [337-340]. 
Various results are presented that range from almost no asymptomatic children to an 
equal distribution of symptomatic and asymptomatic children in virus positive cases. 
Most common viruses associated with asymptomatic infection were HRV, HEV, and 
HCoV. Influenzaviruses, RSV, and AdV were rare findings in asymptomatic children. 
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Table 4. Microbiological findings in 90 episodes of febrile neutropenia revealed by bacterial blood 
culture and real-time PCR in blood and NPA. 
Single virus 
in NPA 
Co-presence 
of virus in 
NPA 
Virus in 
blood 
Bacteria 
in blood 
Co-presence 
of virus and 
bacteria 
Episodes with 
at least one 
agent detected 
Episodes with 
no agent 
detected 
n=21 
(23%) 
n = 9 
(10%) 
n = 4 
(4%) 
n = 10 
(11%) 
n = 11 
(12%) 
n = 54 
(60%) 
n = 36 
(40%) 
HRV: 10 HRV, AdV B19: 2 G+ : 4 HRV: 5 G+ 
AdV: 3 HRV, HBoV CMV: 1 G- : 6            3 G - 
KIPyV: 3 HRV, OC43 EBV: 1 
HKU1: 2 
HRV, 
WUPyV PIV3: 2 G + 
HBoV: 1 
NL63: 1 KIPyV, HEV KIPyV: 1  G+ 
OC43: 1 KIPyV, HBoV HBoV 
RSVB, HKU1 
RSVB, HKU1 
HMPV, NL63 
NOTE. AdV, adenovirus; B19, erythrovirus B19; HBoV, bocavirus; CMV, cytomegalovirus; CRP, C-
reactive protein; EBV, Epstein-Barr virus; EV, enterovirus; G+, Gram positive bacteria; G−, Gram negative 
bacteria; HKU1, coronavirus HKU1; HMPV, human metapneumovirus; HRV, human rhinovirus; KIPyV, 
KI polyomavirus; NL63, coronavirus NL63; NPA, nasopharyngeal aspirate; OC43, coronavirus OC43; 
PIV3, parainfluenza virus 3; RSV, respiratory syncytial virus; WUPyV, WU polyomavirus 
  
 
 
Independently of viral detection method used, the overall yield of potential etiological 
agents of febrile neutropenia increased significantly with extended viral diagnostics 
(Figure 10). This finding motivated us to conduct yet another study with a similar aim 
(Paper IV). However, as discussed in this section, viral findings can be made in 
asymptomatic individuals, and, as thoroughly penetrated in previous parts of the thesis; 
viral findings are not always associated with fever. Therefore we included afebrile 
neutropenic patients as controls in study IV. Moreover, presence of virus was not a 
useful parameter to predict non-bacterial fevers. In 24% of the cases when a virus was 
detected there was a concurrent bacterial infection. The corresponding proportion when 
virus was absent was even less, 22%.  
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Figure 10. Distribution of viruses and bacteria in the 90 episodes of febrile 
neutropenia. Viruses detected by either a conventional viral detection method or PCR. 
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5.3 PAPER III - NASAL SWAB VERSUS NPA FOR VIRAL DETECTION 
 
In the study described in paper II, one of the most frequent explanations for denial to 
participate was to avoid the use of NPA. The method is, from a strict clinical 
perspective, harmless and should not be painful. It could, however, be frightening for a 
child since a long catheter is used and the suction device can be noisy. Furthermore, the 
technique is somewhat complicated. Using a swab to collect nasal secretion has been 
shown in many studies to be a rather proper alternative [341-345], but conflicting 
results exist [346-348]. Most studies are performed on symptomatic children, and the 
detection methods and viruses sought for differ. Both conventional viral detection 
methods and PCR assays have been used with foremost RSV and influenzavirus as 
subjects for investigation. Different depths ranging from 1-4.5 cm have been used, as 
well as nasopharyngeal swabs (NPS). In addition to the lack of a consensus from the 
literature, we also suspected that fNS would be insensitive in immunosuppressed 
individuals due to an altered inflammatory response to infection with subsequent less 
nasal secretion.  
 
In the first part of the study described in paper IV, we collected nasal secretion with 
fNS in parallel to NPA. If the fNS showed acceptable sensitivity it was supposed to 
replace the NPA in the further study. Although several reports have suggested that 
sensitivity increases when the nasopharynx is sampled instead of the nasal cavity [342, 
349], a relationship between reported depth and sensitivity is not evident (Table 5). In 
fact, a comparison of fNS and NPS showed that the use of nasal swabs was accurate but 
significantly less painful than nasopharyngeal swabs for virus diagnosis. We thus chose 
to insert the fNS to a depth of 2-3 cm. 
 
From the first 98 pairs collected, the number of positive samples detected by either 
method was 20. Only thirteen of these (65%) were detected by the fNS. The number of 
positive samples is small, but the upper limit in the 95% confidence interval for the 
overall sensitivity was 85%; an unacceptable low sensitivity for us to replace an 
established method. Illustrative of this is the fact that we would need to collect 54 
additional double-positive pairs, without any additional negative swabs, in order to 
reach sensitivity above 90%. Thus, we decided to continue using NPA. 
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Table 5. Summary of studies comparing swabs and nasopharyngeal aspirates. 
Study 
Depth 
(cm) PCR Viruses 
Sensitivity 
(range)a 
Sungb [345] 1-1.5 No RSV, Flu A, PIV, 
AdV 
 
69% overall 
(PIV 49% –AdV 89%) 
Sungb [345] 1-1.5 Yes RSV, Flu A, PIV, 
AdV 
 
81% overall 
(RSV 67% –PIV 95%) 
Macfarlane [347] 2 No RSV 
 
66% 
Heikkinen [343] 2-3 No RSV, Flu A+B, PIV, 
AdV, HRV, HEV 
 
81% overall 
(RSV 76% –Flu 92%) 
Öhrmalm 2-3 Yes RSV, Flu A+B, 
HRV, HEV, HMPV, 
HBoV 
 
65% overall 
HRV 78% 
Stensballe [346] 2-3 No RSV 
 
73% 
Abu-Diab [342] 4.5 No RSV, Flu A, PIV, 
AdV 
 
98.5% overall 
(AdV 89% –Flu 100%) 
Frayha [350] NPS No RSV, Flu A+B, PIV, 
AdV 
 
85% overall 
(RSV 90%) 
Ahluwalia [351] NPS No RSV 
 
65% 
Cruz [352] NPS No RSV, Flu A+B, PIV, 
AdV, HRV, HEV 
57% overall 
(HEV 54%, AdV 86%) 
NOTE. RSV, respiratory syncytial virus; Flu, influenza virus; PIV, parainfluenza 
virus; AdV, adenovirus; HRV, human rhinovirus; HEV, human enterovirus; HMPV, 
human metapneumovirus; HBoV, human bocavirus. 
a Between the virus with the lowest sensitivity to the virus with the highest 
sensitivity. If not reported, or too few numbers, single values of sensitivity are 
presented 
b Same study using different viral detection methods 
 
 
 
. 
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5.4 PAPER IV - VIRUSES IN NEUTROPENIC ADULTS WITH AND 
WITHOUT FEVER 
 
In study II, we found virus in a rather large proportion of the febrile episodes. However, 
it is not evident, nor likely, that all viruses found are true etiological agents. To further 
determine causality, we compared the prevalence of viruses in neutropenic patients 
with and without fever. The study described in paper IV is similar to study II but differs 
in some aspects; an adult cohort is investigated instead of a pediatric, the panel of 
viruses looked for differ slightly and does not utilize conventional methods, and, as 
mentioned, the study includes afebrile neutropenic patients as controls. Furthermore, 
additional data on common cell populations in peripheral blood was gathered. 
 
As compared to the 50% in the pediatric study, we found one or more viral pathogens 
in 42% of the 144 episodes of febrile neutropenia (Figure 11). Half of these pathogens 
were detected in NPA. Bacterial infection, foremost bacteremia, was present in 35% of 
the episodes, and in one-third of these cases a viral pathogen was found. Conversely, in 
one-third of the virus positive cases, a bacterial infection was determined. Thus, viral as 
well as bacterial infections were more commonly a single infection rather than a co-
infection. 
 
 
 
 
Figure 11. Distribution of viruses and bacteria in the 144 episodes of febrile 
neutropenia and the proportion of viruses detected in peripheral blood and 
nasopharyngeal aspirate (NPA), respectively. 
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Except for the absence of HCoV and PIV, the proportion of detected respiratory viruses 
in NPA was expected; HRV were present in 13 episodes followed by AdV with 7 
episodes. These two viruses were the only represented in the control group. 
Influenzavirus and RSV were equally represented with 5 episodes each, followed by 
HMPV with 2 episodes. As described earlier, HRV seems to be less pyrogenic, and it is 
thus expected to find this virus, if any, in the control group. Rather surprisingly, the 
predominant virus in blood was BKV which is a common cause of hemorrhagic cystitis 
in allo-HSCT recipient [199, 200]. In a total of 18 episodes the virus was detected, but 
with low copy numbers. The second most common virus in blood was CMV, again 
another virus commonly detected post HCST. No one of the controls had detectable 
CMV in blood, and only in one afebrile patient BKV was detected. B19 and EBV were 
also common pathogens in the fever-group, but for EBV the prevalence was equally 
high in the fever-group as in the control group. The copy numbers were low and it is 
unlikely that the pathogens found in blood caused disease. However, could they have 
induced fever? 
 
 
 
 
Figure 12. Difference in virus prevalence between the neutropenic patients with and 
without fever. The p value refers to the univariate analysis. 
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In summary, a significant difference in virus prevalence was found between the groups 
(Figure 12). This was true for viruses in NPA and blood separately as well. 
Unfortunately, the controls were also significantly less immunosuppressed than the 
febrile patients. However, the difference of the immunological status between the virus-
positive and the virus-negative patients was not statistically significant (Figure 13) 
except for the T helper cells (Figure 14). 
 
 
Figure 13. Comparison of lymphocyte and NK cell count (cells/L) for the febrile and 
afebrile patients as well as for the virus-infected and virus-free patients. The dashed 
line represents the reference interval used at the routine laboratory. *, p<0.05; ***, 
p<0.001. 
 
 
 
 
Figure 14. Comparison of helper T cell count (cells/L) for the febrile and afebrile 
patients as well as for the virus-infected and virus-free patients. The dashed line 
represents the reference interval used at the routine laboratory. *, p<0.05; ***, 
p<0.001. 
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In an attempt to rule out possible confounding factors that was detected when 
comparing the fever-group and the controls regarding several parameters, we created a 
multivariate regression model. The association remained and no other factor, including 
immunological status, could thus better explain the association between fever and 
presence of virus. Furthermore, URTS were by far more frequent in patients with virus 
detected in NPA (OR=4.4, p<0.001). 
 
Nevertheless, there are two major considerations to take into account; (1) the sample 
size is rather small which could lead to “small sample bias” in a regression model; (2) 
the most important confounding factor was not measured, namely bacterial infections 
not detected by conventional bacterial culture. In two recent studies, PCR improved the 
microbiological documentation of infections in febrile neutropenia [353, 354], and 
maybe extended bacterial diagnostics could have explained the fever in our study better 
than the viruses. Not surprisingly, we failed to identify laboratory parameters that could 
reliably distinguish patients with different infections. Within the fever group there were 
no differences in CRP according to type of infection. This was also true within the 
control group. The mean CRP in the fever group was however significantly higher than 
the mean CRP for the controls. However, this finding is unfortunately of no clinical 
relevance. As in the pediatric study, a virus finding could not help predicting a non-
bacterial fever. Bacteria were detected in 31% of the virus-positive cases, whereas in 
the virus-negative group, a total of 38% had positive bacterial culture.   
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The study described in paper I differs from the studies described in paper II and IV. 
The attempt to determine the incidence of AdV infections in allo-HSCT recipients was 
motivated by the knowledge that AdV is associated with morbidity and mortality in this 
patient category. A high incidence of AdV infection and AdV disease in our study 
could have supported yet another clinical trial with evaluation of known and newfound 
risk factors. Preemptive treatment in randomly selected patients with AdV detected in 
plasma would further have increased our knowledge about the clinical course upon 
infection. Despite the low number of AdV infections and absence of associated disease 
in our study, there are good reasons not to leave the matter aside. The incidence could 
vary with changed transplant regimens; for example usage of T-cell depleted graft or 
increased proportion of pediatric recipients would motivate reinforced attention. 
Furthermore, as such a great number of AdV serotypes exist, it is of major importance 
to have a reliable PCR assay that are proved to cover the whole panel. The assay should 
be designed to be able to take part in a multiplex assay consisting of other important 
pathogens post allo-HSCT such as CMV, EBV, and BKV. We have designed and 
evaluated an in-house made real-time PCR assay that showed to cover all tested 
serotypes (type 1-50 and 53), and we plan to include it in a fourplex-PCR assay 
designed for post allo-HSCT surveillance.  
 
The papers II and IV describe another approach to improve the clinical care of 
immunocompromised patients. We aimed to identify pathogens that not primarily 
caused severe disease in the patients, but yet were potential etiology to fever. As the 
regimen of prompt empirical antibiotics is widely used upon febrile neutropenia, our 
findings suggest that a proportion of the episodes may be associated with overuse of 
antibiotics. The difference regarding virus prevalence between febrile and non-febrile 
neutropenic patients in paper IV is a promising result. Rather disappointing, however, 
was that the presence of virus did not predict bacterium-free fever. Moreover, there are 
several weaknesses in the study that detract from enthusiasm. Although multivariate 
regression analyses are developed to adjust for not perfectly matched controls, a much 
better study design for this matter is a prospective longitudinal study where the patients 
can be their own controls. Furthermore, results from one homogenous cohort cannot 
always be translated into another. Still, it is better to have reliable results from a small 
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cohort possible to interpret, than to have uncertain results from a heterogeneous group 
such as “hematological patients”.  Thus, a smaller but yet more homogenous patient 
category such as NHL should be investigated one at the time rather than grouped 
together. For viral detection, we can be sure from study I that PCR is superior to the 
conventional viral detection methods. In future studies, though, the higher sensitivity of 
NPA compared to fNS must counterbalance the lower inclusion rate. Finally, all 
relevant extended diagnostics should be used in parallel rather than one at the time. 
 
The studies on etiology of febrile neutropenia did not reveal absolutely convincing 
evidence of an association between viral infections and fever. The results are however 
promising and we therefore plan to conduct a prospective longitudinal surveillance 
study on a more isolated group of hematological patients in order to further investigate 
causality. The sampling occasions will include time-points in both the neutropenic 
phase, with and without fever, and the non-neutropenic phase. In addition to the 
extended viral diagnostics, we plan to use comprehensive bacterial and fungal 
diagnostics including PCR technique. Moreover, the patients will be asked for 
epidemiological information in a higher extent than is done per clinical routine. Finally, 
as the most clinical relevant question to answer is whether the patients suffer from a 
bacterial infection or not, we will try to identify reliable predictors thereof. A possible 
subsequent clinical trial with low-risk patients selected to early discontinuation of the 
empiric antibiotic treatment could be based on these predictors. In the trial, a 
continuous improvement of the prediction algorithm could be achieved through a 
similar extended diagnostic approach. Most importantly, these attempts to advance the 
clinical care must be made with minimum risk of endanger the health of the patients – 
step by step. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Antalet personer med nedsatt immunförsvar har paradoxalt nog ökat i takt med 
medicinska landvinningar. Detta beror dels på att patienter med nedsatt immunförsvar 
som delfenomen i en svår sjukdom övelever längre, dels på att behandling i samband 
med transplantation och cancer ofta innefattar cellgifter som trycker ner 
immunsystemets snabbt delande celler. Ett dåligt fungerande immunförsvar innebär en 
ökad risk att drabbas av infektioner, och dessa patienter kan bli svårt sjuka eller till och 
med avlida av infektioner som annars vore banala och självläkande hos personer med 
intakt immunförsvar. 
 
Av denna anledning är resultatet av den ökande mängd genomförda 
stamcellstransplantationer, då patienternas sjuka benmärg byts ut, till stor del beroende 
av hur väl komplikationer i form av svåra infektioner kan upptäckas och kontrolleras 
under det långa efterförlopp som kan vara flera år. Ett belysande exempel på detta är 
den dramatiska minskningen av dödlighet i komplikationer till infektion med 
cytomegalovirus (CMV), som har uppnåtts via införandet av rutinmässig övervakning 
och snabbt insättande av effektiv läkemedelsbehandling mot detta virus. Adenovirus 
(AdV) är ett annat virus som föreslagits spela stor roll som orsak till sjuklighet och 
dödlighet hos dessa patienter, och i vissa studier har närmare hälften av alla 
transplanterade ådragit sig infektion med AdV. Hur vanligt och viktigt detta virus är i 
dessa sammanhang är dock inte tillräckligt utrett för att rutinmässiga kontroller ska 
införas på bred front. För att bättre kunna värdera nyttan av ett sådant införande, gjorde 
vi en studie där vi parallellt med ett befintligt övervakningsprogram för CMV, också 
tog regelbundna prover avseende AdV i blod hos barn och vuxna som genomgått 
stamcellstransplantation. Vi fann att 5% (5/97) av patienterna hade AdV i blodet någon 
gång under uppföljningstiden, och i alla fallen utom ett återfanns ett lågt antal 
viruspartiklar talande för en låggradig infektion. Ingen av patienterna visade tecken till 
sjukdom relaterad till AdV. Dessa resultat tyder på en mindre betydelse av AdV-
infektion hos denna patientkategori än vad flertalet tidigare rapporter visat. Dock skulle 
vi med stor sannolikhet påvisat fler AdV-infektioner om vår studie hade inkluderat 
patienter med fler riskfaktorer för AdV-infektion efter transplantation. Förutom låg 
ålder, finns andra kända riskfaktorer för AdV-infektion hos transplanterade som de 
flesta direkt eller indirekt anknyter till graden av nedtryckt immunförsvar. I vår studie 
kunde vi finna två nya sådana riskfaktorer som inte tidigare rapporterats. Ökad risk sågs 
för patienter med diagnosen myelodysplatiskt syndrom som anledning till 
transplantation, samt de som fick benmärg som stamcellskälla i stället för stamceller 
från perifert blod eller navelsträngsblod. Även om intensiv övervakning och en 
eventuell antiviral behandling inte hade påverkat det kliniska förloppet hos patienterna i 
denna studie, kan strategin ändå vara aktuell för andra situationer där patienter med fler 
riskfaktorer genomgår ett transplantationsförfarande som trycker ned immunförsvaret 
än mer. 
 
En annan kategori av patienter med kraftigt påverkat immunförsvar är patienter som 
behandlas med upprepade cellgiftskurer mot cancer. Kort efter behandling sjunker 
antalet vita blodkroppar drastiskt (neutropeni) och i händelse av feber måste patienterna 
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åka till sjukhus för inläggning med intravenös behandling med antibiotika, eftersom 
man vet att bakteriell infektion hos dessa så kallade neutropena feberpatienter kan vara 
livshotande. Diagnostiken av vad som orsakar febern riktas i praktiken traditionellt mot 
att leta efter bakterier, och i ungefär en tredjedel av fallen lyckas man med detta, men i 
de övriga två tredjedelarna förblir orsaken okänd. Det finns alltså anledning att tro att 
febern inte alltid orsakas av bakterier, och att man i stället skulle kunna fastställa t.ex. 
virus som orsak om man bara letade efter dessa medelst relevant provtagning. 
Vinsterna vore stora, eftersom man då skulle kunna skilja ut vilka patienter som är i 
behov av antibiotika och som måste stanna inneliggande på sjukhus. För de med 
virusinfektion skulle man kanske i en framtid kunna ändra handläggningsrutinerna och 
medge hemgång utan antibiotika. Detta skulle betyda minskad tid på sjukhus med ökad 
livskvalitet för patienterna under denna redan svåra period i deras liv, och därtill 
minimera risken för ytterligare infektioner med vanliga sjukhussmittor. Minskad 
användning av antibiotika minskar också risken för resistensutveckling och 
opportunistiska infektioner, t.ex. med svamp. Totalt skulle detta även reducera 
sjukvårdskostnaderna, vilket åtminstone kan vara ett krasst sjukvårdspolitiskt argument. 
Av dessa anledningar har vi därför i två stora studier, undersökt möjligheten att med 
utökad virusdiagnostik vid neutropen feber åstadkomma ett underlag för en framtida 
förändring av den kliniska handläggningen av dessa patienter. Både barn och vuxna 
patienter har ingått i studierna och virusdiagnostiken har riktats mot en bred panel av 
utvalda virus som vi har goda skäl att anse som de mest potenta att orsaka feber i denna 
patientgrupp. Det handlar dels om virus som normalt ligger vilande hos friska individer, 
men som kan blossa upp vid nedsättning av immunförsvaret, dels om virus som är 
vanligt förekommande i samhället, däribland flera förkylningsvirus och influensa. Vi 
undersökte förekomsten av dessa virus i blod och i de övre luftvägarna hos patienterna, 
och kunde samtidigt göra jämförelser mellan olika provtagnings- och 
påvisningsmetoder. Hos barn fann vi virus i hälften av fallen och de återfanns 
framförallt i luftvägarna. Totalt, inklusive episoderna där bakterier bedömdes vara 
orsaken till feber, lämnades endast ca 40% av fallen utan något mikrobiologiskt fynd. 
Motsvarande siffror hos vuxna patienter var snarlika med virusfynd i drygt 40% av 
fallen. Här återfanns dock ungefär hälften i luftvägarna och hälften i blod. När vi 
jämförde med en kontrollgrupp från samma patientkategori, men utan feber, fann vi en 
markant skillnad i förekomst av virus. Här återfanns ett virus i endast 13% av fallen, 
jämnt fördelade mellan blod och luftvägar. Den kliniskt viktiga uppgiften att utesluta 
bakteriell infektion, visade sig dock ej görbart endast genom att påvisa förekomst av 
virus. Andelen bakteriella infektioner var nämligen ungefär lika stor hos dem som hade 
respektive inte hade virusinfektion. Den höga andelen virus vid neutropen feber och det 
faktum att motsvarande feberfria patienter inte hade virus i samma utsträckning, ger 
dock hopp om att våra fynd kan spela en viktig roll tillsammans med andra variabler i 
en framtida algoritm för handläggningen av dessa patienter. Detta motiverar därför till 
fortsatt forskning som nu är under planering i vår grupp. 
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